**SCOPE**

**Scorecard for osteoporosis in Europe**

**About SCOPE**

The *S*core*C*ard for *O*steo*P*orosis in *E*urope (SCOPE) is an independent project that seeks to raise awareness of osteoporosis care in Europe. SCOPE permits an in depth comparison of the quality of care of osteoporosis across the 27 member states of the European Union (EU27).

Osteoporosis is a complex disease that can be treated and managed in a number of ways. Improvements in medication and diagnostic techniques in the past 25 years have served to reduce the risk of osteoporotic fractures. In Europe, however, research has shown significant heterogeneity in the different national approaches to the management of the disease.

The scorecard summarises key indicators of the burden of osteoporosis and its management in each member state of the European Union to draw attention to the disparities in healthcare provision that can serve in the setting of benchmarks to inform patients, healthcare providers and policy makers in the EU.

**The aim of this scorecard is to stimulate a balanced, common and optimal approach to the management of osteoporosis throughout the EU.**
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**A letter to all Europeans**

The statistics are startling.

One in three women and at least one in six men will suffer an osteoporotic fracture in their lifetime, and it is estimated that more than ten million men and women are at high risk of osteoporotic fractures in the European Union.

Osteoporosis and the 3.5 million fractures it causes cost the healthcare systems of Europe in excess of €39 billion each year based on data for 2010. But numbers don't tell the full story. For the individuals who suffer fractures as a result of the disease, the stories are personal. Pain, disability, reduced mobility and long-term disability are all too frequent. Additionally, fractures related to osteoporosis result in early death. About 43,000 deaths occur each year in Europe as a direct consequence of hip or spine fractures.

The primary purpose of the scorecard for osteoporosis in Europe is to help individuals reduce their risk of osteoporosis and to ensure that all Europeans have access to the best diagnosis and treatment. Components that are critical to achieving this goal include government policy, access to assessment of risk and access to medications. This scorecard allows Europeans to measure how well their country is able to access these elements through the publicly funded healthcare systems. It also provides a benchmark to measure future progress.

Our research reveals that facilities and access to testing for osteoporosis are far from adequate. Access to drug treatment that can help prevent fractures varies markedly from country to country; in some member states, individuals with osteoporosis are restricted from accessing effective treatment options. Less than half of women at high risk of fracture are treated despite the high cost of fractures and the availability of affordable medications.

Action is required. The national osteoporosis societies of the International Osteoporosis Foundation are calling for a Europe-wide strategy and parallel national strategies to provide coordinated osteoporosis care and to reduce debilitating fractures and their impact on individual lives and the healthcare system. We welcome the opportunity to partner with governments at the national and European level to develop and implement these strategies. Together we can improve the bone health of all in Europe.

\[Signatures to be invited from Scorecard panel\]

**Introduction**

*The basis for SCOPE*

SCOPE comprises an independent panel of experts that have considered the information available on the burden of osteoporosis and healthcare provision and uptake in the EU27. SCOPE draws on independent research from two major sources. The first was a series of regional audits of the International Osteoporosis Foundation (IOF) \[1--3\]. This information base was broadened and updated by IOF to inform the SCOPE panel members through its outreach to over 30 national osteoporosis societies throughout Europe. The second major resource was a comprehensive report undertaken by the IOF and the Europian Federation of Pharmaceutical Industry Associations (EFPIA) on the burden of osteoporosis in the largest countries of the EU \[4\]. This was subsequently extended to all counties of the EU \[5, 6\] and made available to the panel.

From the information available, the panel developed indicators of osteoporosis that could be applied to each member state, categorised as:*Burden of disease*---including the burden of osteoporosis, fractures and forecasts for the future*Policy framework*---such as the availability of public health programmes*Service provision*---including assessment and treatments of osteoporosis*Service uptake*---e.g. the proportion of men and women at high risk that do not receive treatment (treatment gap).

Comparisons of indicators across countries are often limited by a lack of consistency of information retrieved across countries. One of the strengths of the resource documents considered by the panel is the consistency of the approach in documenting the burden of disease, wherever possible, by the use of country-specific information. The Scorecard Panel and the IOF invested substantial efforts to ensure that the European audits were updated by means of a structured questionnaire that was sent to all IOF national societies and key opinion leaders in each country. Discrepancies and ambiguities were resolved by correspondence. The panel recognised that consistency does not necessarily equal accuracy and, where information across countries is based only on opinion, this has been highlighted. The questionnaire is available on the web site of the IOF (<http://www.iofbonehealth.org/>).

For each domain, a synthesis was summarised and tabular information provided for each member state which appears in the body of the report. For key indicators, termed scorecard elements, the information was scored and the basis for the score allocation provided. For example, the remaining lifetime risk of a hip fracture at the age of 50 years ranged from 7.0 to 25.1 % in women from the different countries of the EU. Counties were categorised by tertile of risk. High risk countries were colour coded red, intermediate risk coded orange and low-risk countries coded green. A similar 'traffic light' approach was applied to each element in each domain. The resulting scorecard elements were then assembled on a single sheet to provide a unique overview of osteoporosis in Europe. It will enable healthcare professionals and policy makers to assess their country's general approach to the disease and provide indicators to inform future provision of healthcare.

Some caveats are appropriate in the interpretation of scores. Green is not necessarily 'good' and red is not necessarily 'bad'. An example of the former is the uptake of fracture liaison services. Whereas counties coded green have up to 10 % of hospitals with such a service, the panel would consider that 50 % or more hospitals would be an appropriate target. Coding all countries red would, however, not permit the comparative performance of one country against another. Other examples are highlighted in the text.

*Osteoporosis*

Osteoporosis is characterized by reduced bone mass and disruption of bone architecture, resulting in increased bone fragility and increased fracture risk \[7\]. The publication of a World Health Organization (WHO) report on the assessment of fracture risk and its application to screening for postmenopausal osteoporosis in 1994 provided diagnostic criteria for osteoporosis based on the measurement of bone mineral density (BMD) and recognised osteoporosis as an established and well-defined disease that affected more than 75 million people in the United States, Europe and Japan \[8\].

The diagnostic criterion for osteoporosis is based on the measurement of BMD **\[**9\]. Bone mineral density is most often described as a *T* score that describes the number of SDs by which the BMD in an individual differs from the mean value expected in young healthy women. The operational definition of is defined as a value for BMD 2.5 SD or more below the young female adult mean (*T* score less than or equal to −2.5 SD). BMD at the femoral neck is the international reference standard \[10\]. The consequences of low BMD reside in the fractures that arise. The relationship between BMD and fracture is continuous in that the lower the BMD, the higher the fracture risk \[11\].

*Osteoporotic fractures*

The most common fractures associated with osteoporosis are those at the hip, spine, forearm and humerus but many other fractures after the age of 50 years are associated with low BMD and should be regarded as osteoporotic \[12\]. These include fractures of the ribs, tibia, pelvis and other femoral fractures. The causation of fractures is not solely dependent on BMD but is multifactorial. Many factors such as liability to falling, age etc. contribute to the risk of fracture. Thus, not all fragility fractures occur in individuals with a BMD *T* score of −2.5 SD, and the terms osteoporosis, fragility fracture and osteoporotic fractures have inherent ambiguities. For the purpose of this report, the term osteoporosis is used in a generic sense rather than a specific sense unless otherwise specified. For example the 'cost of osteoporosis' refers to the cost of fractures at sites associated with osteoporosis irrespective of the *T* score.

The incidence of fragility fractures increases markedly with age, though the rate of rise with age differs for different fracture outcomes. For this reason, the proportion of fractures at any site also varies with age. For example, forearm fractures account for a greater proportion at younger ages than in the elderly. Conversely, hip fractures are rare at the age of 50 years but become the predominant osteoporosis fracture from the age of 75 years. In women, the median age for distal forearm fractures is around 65 years and for hip fracture, 80 years. Thus, both the number of fractures and the type of fracture are critically dependent on the age of the populations at risk.

Hip fracture is the most serious osteoporotic fracture. Hip fracture is painful and nearly always necessitates hospitalisation and surgical intervention. Up to 20 % of patients die in the first year following hip fracture, mostly as a result of serious underlying medical conditions \[13\], and less than half of survivors regain the level of function that they had prior to the hip fracture \[14\]. Thus, not all deaths associated with hip fracture are due to the hip fracture event and it is estimated that approximately 30 % of deaths are causally related. When this is taken into account, hip fracture causes more deaths than road traffic accidents in Sweden and about the same number as those caused by breast cancer \[15\].
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Chapter 1. Burden of disease

**1a Economic framework**

**Domain**

Burden of disease---background information

**Background and aims**

Cost of illness studies provide no direct guidance on how resources should be allocated, but may provide relevant information concerning the consequences of a disease that may inform policy. Such data may aid decisions concerning societal resource allocation for research, development, and funding of new treatments. Results from cost-of-illness studies can also be utilised to assess the long-term consequences and value of medical progress.

The objective of this background section is to estimate the current cost of osteoporotic fracture in the countries of the European Union set against the wealth of the nation and the healthcare spend of that wealth. A more detailed consideration of the cost is given in Chapter 1b.

**Methods**

Direct costs of fractures in men and women from the EU27 aged 50 years or more were expressed as a proportion of total health care spending in the respective country \[1\] and as the cost per capita of the general population \[2, 3\].

**Results**

Health care spending varied markedly between countries, ranging from €500 million in Malta to €281 billion in Germany (Table [1](#Tab1){ref-type="table"}). The total spend on healthcare in the European Union amounted to €1,260 billion, with the cost of osteoporotic fractures representing approximately 3 % of the healthcare spend (€37.4 billion in 2010). This clearly demonstrates a substantial impact on the present healthcare budgetTable 1Cost of osteoporotic fractures in relation to the population and health care spending (2010)CountryPopulation (000)Health care spending (€000,000)Health care spending (% GDP)Health care spending (€/capita)Fracture cost (% health care spending)Austria8,39231,00010.23,7412.5Belgium10,71242,0009.93,9031.5Bulgaria7,4932,7007.23541.6Cyprus1,1031,0006.29375.2Czech Republic10,49311,0006.91,0872.2Denmark5,55126,00010.84,7594.0Estonia1,3391,0005.27473.0Finland5,36518,0008.23,2632.2France62,634227,00011.03,6172.1Germany82,056281,00010.63,4183.2Greece11,35824,0009.52,1262.9Hungary9,9857,0008.37093.6Ireland4,47015,0007.53,3991.5Italy60,098148,0009.02,4614.7Latvia2,2521,0006.65203.2Lithuania3,3252,0006.25462.6Luxembourg5063,0007.36,2350.7Malta4165008.41,1083.8Netherlands16,61064,0009.43,8291.3Poland38,27625,0006.26602.4Portugal10,67619,00010.21,8263.0Romania21,4867,0004.53092.0Slovakia5,4633,0007.11,0923.6Slovenia2,0286,0008.41,4850.9Spain45,317102,0008.42,2472.8Sweden9,29434,0009.23,7094.3UK61,899159,0008.22,5643.4EU27498,5971,260,0002,5283.0

The share of health care spending allocated to osteoporosis varied across countries, ranging from 0.7 % in Luxembourg to 5.2 % in Cyprus (Fig. [1](#Fig1){ref-type="fig"}). As might be expected there was a significant but modest relationship between the amount spent on osteoporosis, GDP and the incidence of osteoporotic fractures.Fig. 1Proportion (%) of the total direct healthcare spend in the EU27 countries allocated to osteoporotic fractures \[3\]

The estimated cost of osteoporosis may be compared to the cost of other diseases. However, given that the EU27 is a relatively new construct, few directly comparable studies exist. Furthermore, methodological differences render some studies difficult to compare. However, a few studies are available conducted in a similar geographic area with comparable methodology.

In a report issued by the European Brain Council, the yearly societal costs for a number of brain disorders in the EU27 were estimated at €105 billion for dementia, €43.5 billion for headache, €14.6 billion for multiple sclerosis, and €13.9 billion for Parkinson's disease \[4\].

The cost of coronary heart disease and cerebrovascular disease in the European Union (25 countries) has been estimated at approximately €45 billion and €34 billion, respectively, at 2003 prices \[4\]. The cost of epilepsy in the European Union (25 countries) has been estimated at €15.5 billion at 2004 prices. Healthcare costs comprised 18 % of costs, whereas direct medical costs and productivity losses represented 27 % and 55 %, respectively \[5\]. Thus, in relation to other common non-communicable diseases osteoporosis has major economic consequences for society.

**Score allocation**

None---not a score card element

**Comment**

It should be noted that not all fracture-related costs come from the countries' healthcare budgets (e.g. long-term care and variable reimbursement policies). Data on healthcare spending are for 2006.
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**1b Healthcare cost of osteoporotic fractures**

**Domain**

Burden of disease---background information

**Background and aims**

Cost of illness studies can take on a societal perspective (includes all cost carried directly or indirectly by society) or a payer perspective (usually includes all costs carried by the healthcare and social system). Both play an important role in the understanding of disease implications and may aid decisions concerning societal resource allocation for research, development, and funding of new treatments. Results from cost of illness studies can also be utilised to assess the value of medical progress.

The main objective of this section is to provide detail on the current cost of osteoporotic fractures in the countries of the European Union.

**Methods**

The cost of osteoporotic fractures was first determined without intangible costs (i.e. the monetary value of QALYs lost due to death and disability) \[1\]. Costs of fracture-related productivity losses were not included because they are only incurred in patients below retirement age---median age 60 years in Europe \[2\]---and are less than 1 % of hip fracture cost in Sweden \[3\].

Empirical but incomplete cost estimates were available for Austria, Belgium, Czech Republic, Denmark, Finland, Germany, Ireland, Italy, Netherlands, Portugal Slovenia, Sweden and the UK. For countries where fracture costs were not found, the costs were imputed from the nearest country available by adjusting for differences in healthcare price levels between the relevant countries.

Costs were divided into the direct cost of fractures in 2010, the ongoing cost in 2010 of fractures occurring before 2010 ('long-term disability'), and the cost of intervention for osteoporosis. It was conservatively assumed that fractures other than those at the hip did not incur any longer-term costs after the first year. Hip fracture costs in the second and following years after the event were based on the proportion of patients that become dependent in the long-term.

The health burden of osteoporosis was additionally measured in terms QALYs lost. The QALY is a multi-dimensional outcome measure that incorporates both the quality (health related) and quantity (length) of life. The value of a QALY was set at value of 2× GDP per capita \[4\].

**Results**

The direct cost of osteoporosis in the EU27 from the fractures that occurred in 2010 was €24.6 billion (Table [2](#Tab2){ref-type="table"}). To this is added the ongoing cost in 2010 incurred by fractures that occurred before 2010 which amounted to €10.7 billion (long-term disability). The cost of pharmacological intervention (assessment and treatment) was €2.1 billion. Thus, the total direct cost in the EU27 (excluding the value of QALYs lost) amounted to €37.4 billion in 2010. First year, subsequent year, and pharmacological costs accounted for 66, 29 and 5 % of the costs respectively.Table 2Cost of osteoporosis in the EU27 in 2010 (€ million, 2010) \[1\]CountryIncident fracturesLong-term disabilityInterventionTotalCost per capita (€)QALYs lost (€m)Austria54022930799951 903Belgium41915729606571 734Bulgaria30111426118Cyprus34712524778Czech Republic165565327326630Denmark718300371,0551901 704Estonia2271302259Finland2691041038371829France3,1791,3293464,853778 309Germany6,6172,0553369,00811014 927Greece48810291680601 263Hungary127304019720464Ireland125623522350426Italy4,2692,4023617,0321178 771Latvia2972381772Lithuania32123471481Luxembourg15422243148Malta1142174124Netherlands36043429824501 863Poland3551627659316991Portugal2932642057754580Romania883571296339Slovakia76191110720283Slovenia361375628168Spain1,3721,0554142,842633 271Sweden927529291,4861602 666UK3,9771,3281035,408878 698EU2724,57410,7182,08737,3787557 243

Whilst the proportion of costs for pharmacological intervention to total costs was low on average, some inter-country variation was observed: the lowest proportion of costs attributable to intervention was observed in Sweden (2 %) and the highest costs in Hungary (4.7 %). Hip fractures were estimated to account for 54 % of the total costs, other fractures 39 %, vertebral fractures 5 %, and forearm fractures 2 %.

On average, the direct cost of osteoporotic fractures was €75 for each individual in the EU27. There was a large variation in the 'osteoporosis tax' (cost per capita) which was highest in Denmark (€188/person) and Sweden (€159) and lowest in Bulgaria (€6) and Romania (€6). The heterogeneity of this cost is in part related to the incidence of fracture (*r* = 0.67, *p* = 0.001) and the healthcare spend per capita (*r* = 0.63, *p* = 0.004).

The cost of QALYs lost in the EU27 was substantial amounting to €57.2 billion, giving a total cost of €94.6 billion in 2010. Intervention costs amounted to 2 % of the total cost (Fig. [2](#Fig2){ref-type="fig"}) and 5 % of the direct costs.Fig. 2Components (%) of the cost of osteoporosis and fractures \[1\]

**Score allocation**

None---not a score card element

**Comment**

There are few directly comparable studies in other non-communicable diseases that exist.

For coronary heart disease, healthcare costs, productivity losses, and informal care comprised 51, 34 and 15 %, respectively. Costs for pharmacological treatment accounted for 12 % of the total cost, substantially higher than that for osteoporosis. For cerebrovascular disease, healthcare costs, productivity losses, and informal care comprised 61, 18 and 21 %, respectively. The cost for pharmacological treatment accounted for 3 % of the total cost for cerebrovascular disease \[5\], somewhat lower than that for osteoporosis.
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**1c Men and women with osteoporosis**

**Domain**

Burden of disease---background information

**Background and aims**

Osteoporosis is diagnosed using dual-energy X-ray absorptiometry (DXA) to measure bone mineral density (BMD). The diagnostic reference site is the femoral neck using the NHANES III reference data \[1\]. Osteoporosis is diagnosed when the BMD measured at the femoral neck is more than 2.5 standard deviations below the average value of the young white female population \[2\]. The aim of this background information was to document the burden of osteoporosis as judged by densitometric criteria.

**Methods**

Accurate estimates of the prevalence of osteoporosis require country-specific data on the distribution of femoral neck BMD. However, large population-based reference data are lacking in the EU27 countries. For the purposes of this report, it is assumed that the mean femoral neck BMD is similar across EU countries at the age of 50 years as is the rate of bone loss at the femoral neck with age. The same assumptions have been used elsewhere \[3--8\]. On this basis, the prevalence of osteoporosis was calculated from the age- and sex-specific BMD in the NHANES III study. These prevalence estimates were then applied to the population demography in each EU country \[9\].

**Results**

In 2010, there were approximately 27.6 million men and women with osteoporosis in the EU27, of which 5,500,000 were men and 22,100,000 were women, i.e. there were four times as many women with osteoporosis as there were men. Of all member states, Germany was estimated to have the highest number of individuals with osteoporosis with approximately 1 million osteoporotic men and 4 million osteoporotic women. Overall, the prevalence of osteoporosis was 6.6 and 22.1 % in men and women aged 50 years or more (Table [3](#Tab3){ref-type="table"}). In men over the age of 50 years, the prevalence of osteoporosis varied from 5.9 (Poland) to 7.2 % (Luxembourg). In women, the prevalence ranged from 19.1 (Cyprus) to 23.5 % (France).Table 3Estimated number of men and women with osteoporosis, prevalence in population over 50 years, and prevalence in the total population, 2010 \[9\]CountryMen with osteoporosisWomen with osteoporosisMen and women with osteoporosisPrevalence in male population aged 50 or more (%)Prevalence in female population aged 50 or more (%)Prevalence in total population (%)Austria89,862368,685458,5476.522.25.5Belgium120,695476,875597,5706.622.45.6Bulgaria81,482336,425417,9076.420.95.6Cyprus9,26331,03240,2956.219.33.7Czech Republic103,114425,944529,0586.020.45.0Denmark61,456221,912283,3686.521.15.1Estonia11,64265,78977,4316.222.25.8Finland61,054243,399304,4536.421.55.7France691,1122,784,1983,475,3106.722.55.5Germany1,006,6524,017,2605,023,9126.622.66.1Greece135,202507,505642,7076.922.35.7Hungary94,949452,158547,1076.221.15.5Ireland37,127129,309166,4366.220.03.7Italy749,2373,042,7943,792,0316.923.46.3Latvia19,210111,236130,4466.122.35.8Lithuania27,136148,375175,5116.121.75.3Luxembourg4,54117,42221,9636.121.04.3Malta4,19016,07420,2645.919.84.9Netherlands175,244643,258818,5026.320.84.9Poland338,7561,509,7721,848,5285.820.14.8Portugal117,738475,882593,6206.722.05.6Romania198,065835,8851,033,9506.220.54.8Slovakia42,726188,911231,6375.719.44.2Slovenia20,54389,489110,0326.021.55.4Spain496,3681,952,9872,449,3556.822.65.4Sweden113,722409,373523,0956.922.45.6UK679,4242,527,3313,206,7556.721.95.2EU275,490,51022,029,28027,519,7906.622.15.5

The prevalence of osteoporosis in the entire EU27 population (i.e. all ages) was 5.5 % and ranged from 3.7 % in Cyprus and Ireland to 6.3 % in Italy (Fig. [3](#Fig3){ref-type="fig"}).Fig. 3Components (%) of the cost of osteoporosis and fractures \[1\]

**Score allocation**

None---not a score card element

**Comment**

Although BMD is a strong predictor of fracture risk \[10, 11\], the prevalence of osteoporosis is not used as a score card element because the relationship of osteoporosis to fracture risk varies by age and between countries \[12\]. For this reason, fracture risk is the preferred metric.
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**1d Epidemiology of hip fracture**

**Domain**

Burden of disease---scorecard element

**Background and aims**

Fracture incidence is poorly documented in the EU. The fracture incidence that has been best evaluated is hip fracture. Hip fractures account for the majority of health care expenditure, mortality and morbidity and can be used as a proxy for osteoporosis. There is a marked difference in the incidence of hip fracture worldwide and probably in other osteoporotic fractures \[1\]. Indeed, the difference in incidence between countries within Europe is greater than the differences in incidence between sexes within a country \[2, 3\]. The EU comprises countries with some of the highest hip fracture rates, but the documentation of the size of the problem and the quality of data vary between countries.

The aim of this scorecard element was to summarise the information base available for the incidence of hip fracture.

**Methods**

Studies on hip fracture risk were identified from 1950 to November 2011 by a Medline OVID search. Evaluable studies in each country were reviewed for quality and representativeness and a study (studies) chosen to represent that country. Age-specific incidence rates were age-standardised to the world population in 2010 in men and in women \[1\].

**Results**

National data on hip fracture rates were identified in 17 member states (Table [4](#Tab4){ref-type="table"}). No data were available for four countries (Bulgaria, Cyprus, Latvia, and Luxembourg). In the remaining six countries, regional estimates were identified. For Estonia and Slovenia data were available in women only.Table 4Information available on age-standardised (2010) hip fracture rates (/100,000/year) in countries of the European Union \[1\]YearSampleIncidenceF/MWomenMenAustria2001--5National5012462.0Belgium2005--7National3561692.1BulgariaCyprusCzech Republic2008--9National3742111.8Denmark2004National5742902.0Estonia1991--4Regional225----Finland2000--5National2931801.6France2004National2911262.3Germany2003--4National3461662.1Greece1986--92Regional3261582.1Hungary1999--03National3672061.8Ireland2008--10National4061912.1Italy2007National3341402.4LatviaLithuania2010National2701561.7LuxembourgMalta2003--7National3551602.2Netherlands2005National2491212.1Poland2008Regional2241331.7Portugal2000--2National268982.7Romania2005--9National1981421.4Slovakia2007National4012631.5Slovenia2003National349----Spain1984--91Regional228922.5Sweden1991Regional5392472.2UK1992--3Regional3491402.5

As expected, hip fracture rates were higher in women than in men with a female/male ratio that ranged from 1.4 (Romania) to 2.7 (Portugal). There was a nearly three-fold range of hip fracture rates throughout the EU from 198/100,000 (Romania) to 574/100,000 (Denmark). Thus, the international variation between countries was greater than the differences between men and women within countries.

**Score criteria**

The age-standardised incidence was ranked. Women were chosen since fracture rates are more robust and it permitted the inclusion of Estonia and Slovenia for which no data were available in men. The criteria for categorisation were chosen as described in Table [5](#Tab5){ref-type="table"}.Table 5Criteria for allocating scores

**Score allocation**

The ranked incidence is shown in Fig. [4](#Fig4){ref-type="fig"} and colour coded by category.Fig. 4Annual incidence of hip fracture in women from countries of the EU age-standardised to the world population for 2010 \[1\]

**Comment**

On an international scale, all countries were at moderate or high risk (150--250/100,000 and \>250/100,000, respectively) \[1\].

Reasons for the large variation in fracture risk between countries are speculative, but, ecological studies have shown a weak but significant relationship between hip fracture risk and latitude and socio-economic prosperity \[4\].
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**1e Number of fragility fractures**

**Domain**

Burden of disease---scorecard element

**Background and aims**

The most obvious and serious effect of osteoporosis is the fractures that occur as a consequence of increased bone fragility. This section determines the number of fractures associated with bone fragility in the EU27.

**Methods**

The fractures of interest include those at the hip, spine and forearm as well as osteoporotic fractures at other vulnerable sites (humerus, ribs, tibia, pelvis and other femoral fractures) grouped as other fractures. Information on the incidence of osteoporotic fractures varies between the countries of the EU27. In general, reports on hip fracture incidence are more complete than for fractures at other sites (see Chapter 1d).

The risk of hip fracture was taken from a systematic review of hip fracture incidence \[1\]. For the EU27 countries with incomplete information, incidence was taken from the nearest country where hip fracture incidence was available \[2\]. Where the incidence of fractures other than the hip was not available, the incidence was imputed from the hip fracture incidence in the relevant country, using the relationship between hip fracture incidence and incidence of fracture in other sites in Sweden \[3\].

The number of fractures in each country for each fracture site was computed from the age- and sex-specific estimates of incidence and population demography for 2010 \[4\]. Crude incidence in each country was expressed as the number of fragility fractures per 1000 of the population aged 50 years or more.

**Results**

There were estimated to be 3.5 million new fragility fractures in the EU in 2010---equivalent to 9,556 fractures/day (or 390/h) (Table [6](#Tab6){ref-type="table"}). Almost twice as many fractures occurred in women compared to men. Hip, vertebral, forearm and other fractures accounted for 18, 15, 16 and 51 % of all fractures, respectively.Table 16Characteristics of information available on fracture rates in the European UnionIncidence of hip fractureEstablished National Fracture RegistriesScoreQuality^a^Sample^b^PresentData^c^AustriaGNNo^d^3BelgiumGNYesHip3BulgariaNo0CyprusNo0Czech RepublicGNNo2DenmarkGNYesHip+3EstoniaPRNo1FinlandGNYesHip+3FranceGNNo^d^2GermanyGNYesHip+3GreeceP/F/GRNo1HungaryGNYesHip+3IrelandGNYesHip3ItalyGNNo^d^Hip+2LatviaRYesHip+3LithuaniaFRNo1LuxembourgNo0MaltaGNNo2NetherlandsGNYesHip+3PolandFRNo1PortugalGNYesHip+3RomaniaGNNo2SlovakiaGNYesHip+3SloveniaFNNo2SpainF/GRNo^d^Hip+1SwedenGRYesHip3UKGRYesHip3Responses derived from questionnaire to National Societies^a^Quality: *G* good; *F* fair; *P* poor \[2\]^b^Catchment: *N* national; *R* regional^c^ *Hip* Registration of hip fracture only. *Hip+* Registration of hip and other fracture outcomes^d^Regional registers available

The number of incident fractures per country is shown in Table [7](#Tab7){ref-type="table"}. Germany had the highest number of fractures for all fracture types in both men and women---approximately 724 000 incident fractures in total---predominately reflecting a large population size and comparatively high fracture incidence. Malta and Luxembourg had the lowest number of fractures for all types---(less than 3 000 incident fractures in each country), reflecting small population sizes.Table 7The number of new fragility fractures in 2010 in men and women by country, the population at risk (men and women aged 50 years or more) and the crude incidence (/1000 of the population) \[2\]CountryNew fracturesPopulation at risk (000)Rate/1,000Austria86,5363,04128.5Belgium79,8933,95920.2Bulgaria38,1982,87613.3Cyprus5,12931116.5Czech Republic72,1953,80219.0Denmark66,3582,00333.1Estonia8,68848517.9Finland36,4052,09017.4France376,77422,64516.6Germany724,77433,01022.0Greece85,5184,23620.2Hungary102,4573,68327.8Ireland18,0851,24614.5Italy465,40023,78819.6Latvia14,30581217.6Lithuania15,0741,12713.4Luxembourg270015817.1Malta264115217.4Netherlands75,9475,89312.9Poland167,66413,35012.6Portugal51,8213,92213.2Romania94,2827,28912.9Slovakia38,6341,73022.3Slovenia15,51075920.4Spain204,15115,90512.8Sweden107,0463,48930.7United Kingdom535,87321,63624.8EU273,492,058183,39719.0

When fracture numbers were expressed as a rate of the population at risk, there was a greater than two-fold range in risk that varied from 12.6/1000 in Poland to 33.1/1000 in Denmark.

In addition to pain and disability, some osteoporotic fractures are associated with premature mortality. About 30 % of deaths after a hip or clinical spine fracture can be attributed to the fracture event \[5--7\]. In the EU, there were estimated to be 43,000 deaths causally related to in 2010. Approximately 50 % of fracture-related deaths in women were due to hip fractures, 28 % to clinical vertebral and 22 % to other fractures. Corresponding proportions for men were 47, 39 and 14 %, respectively. Fracture-related deaths by country are shown in Fig. [5](#Fig5){ref-type="fig"}. Note that the variability in death rates is more a reflection of the variable incidence of fractures rather than in standards of care.Fig. 5The number of deaths associated with fracture events expressed per 100,000 of the population added 50 years or more in the EU27 \[2\]

**Score criteria**

The number of fragility fractures in men and women combined in 2010 expressed/1,000 of the population aged 50 years or more was categorised approximately by tertiles as given in Table [8](#Tab8){ref-type="table"}.Table 8Criteria for allocating scores

**Score allocation**

Countries, ranked and categorised by risk, are shown in Fig. [6](#Fig6){ref-type="fig"}. The variation between countries reflects both the fracture risk and the distribution of age and sex in each country.Fig. 6The annual number of fragility fractures in men and women combined expressed/1,000 of the population aged 50 years or more

**Comment**

The calculation of fracture numbers from hip fracture rates assumes that the ratios between age- and sex-specific incidence of hip fracture and fractures of other sites found in Sweden are similar in other countries. This assumption has been shown to hold true for the countries where this has been tested \[3, 8\].

These estimates do not include individuals who in 2010 were suffering the consequences of fractures sustained in previous years.

There are important data gaps in the documentation of the fracture burden between member states which form the component of a further scorecard element (Chapter 2a).
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**1f Lifetime hip fracture probability**

**Domain**

Burden of disease---scorecard element

**Background and aims**

The most serious consequence of osteoporosis in terms of morbidity, mortality and health care expenditure is hip fracture. In the EU, for example, hip fractures comprise only 17 % of the total number of fragility fractures but account for 54 % of the direct costs and 49 % of deaths due to fracture \[1\]. The likelihood of hip fracture can be expressed as fracture probability from a given age over a given time interval (e.g. 10 years).

The aim of this element is to provide estimates of the remaining lifetime probability of hip fracture in men and women at the age of 50 and 70 years.

**Methods**

Hip fracture probability was computed taking both the risk of fracture and the risk of death into account \[2\]. The risk of hip fracture was taken from a systematic review of hip fracture incidence \[3\]. Where possible, the incidence of hip fracture was determined in men and women using 5-year age categories. Where 5-year age intervals were not available, 10 year intervals were used (intervals of greater than 10 years were an exclusion criterion). Mortality statistics of the WHO were used in 5 or 10 year age intervals for the year 2010 \[4\]. The remaining lifetime probabilities were calculated in men and women from the age of 50 and 70 years.

**Results**

Empirical data on hip fracture rates were available for 21 of the 27 EU member states in men and women. No data were available for men from Estonia and Slovenia. Hip fracture incidence is not documented in Bulgaria, Cyprus, Latvia or Luxembourg.

The average remaining lifetime probability of hip fracture in women at the age of 50 years ranged from 7.0 % (Romania) to 25.1 % (Sweden). Thus, there was approximately a three-fold range of lifetime probabilities between countries (Table [9](#Tab9){ref-type="table"}).Table 9Remaining lifetime probability of hip fracture (%) at the ages of 50 and 70 years in men and women by country, 2010 \[3\]CountryLifetime probability (%)At age 50 yearsAt age 70 yearsMenWomenMenWomenAustria8.319.78.820.7Belgium7.818.28.318.9Bulgaria--------Cyprus--------Czech Republic6.914.87.515.6Denmark10.622.111.123.6Estonia--23.3--21.1Finland5.812.46.112.8France5.618.46.319.4Germany5.314.25.615.0Greece8.015.88.615.2Hungary4.110.65.212.0Ireland7.818.28.018.7Italy7.719.27.819.3Latvia--------Lithuania4.411.35.311.9Luxembourg--------Malta5.814.25.814.2Netherlands5.412.55.612.8Poland4.09.73.910.1Portugal4.814.45.314.9Romania3.87.03.77.2Slovakia9.520.39.920.3Slovenia--11.6--12.0Spain4.012.14.312.6Sweden10.925.111.025.4United Kingdom4.813.85.014.6-- denotes no data

Probabilities of hip fracture were approximately two-fold lower in men than in women. In men, hip fracture probability at the age of 50 years ranged from 3.8 % (Romania) to 10.9 % (Sweden). There was a close correlation between hip fracture probability in men and women so that in those countries where fracture probability was high in women, so too was it high in men (Fig. [7](#Fig7){ref-type="fig"}). In Sweden, which had the highest hip fracture probabilities, the hip fracture risk in men (10.9 %) was higher than the hip fracture probability in women from Hungary, Poland or Romania.Fig. 7Remaining lifetime probability of hip fracture (%) in men and women from 21 countries in the EU from the age of 50 years \[1\]

**Score criteria**

The remaining lifetime probability of hip fracture at the age of 50 years was ranked. Women were chosen since it permitted the inclusion of Estonia and Slovenia for which no data were available in men. The criteria for categorisation are shown in Table [10](#Tab10){ref-type="table"}.Table 10Criteria for allocating scores

**Score allocation**

The ranked incidence is shown in Fig. [8](#Fig8){ref-type="fig"} and colour coded by category.Fig. 8Remaining lifetime probability of hip fracture (%) in women in the EU from the age of 50 years \[1\]

**Comment**

Hip fracture probabilities from the age of 70 years were not markedly different from those from the age of 50 years. The reason for this is that increasing death and fracture hazards with age compete in the determination of probability.
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**1g Men and women at high fracture risk**

**Domain**

Burden of disease---scorecard element

**Background and aims**

The advent of FRAX in 2008 \[1\] provided a clinical tool for the calculation of fracture probability. Probability-based assessment is increasingly being incorporated into clinical guidelines in Europe \[2, 3\] and elsewhere. Unlike fracture incidence, the probability of fracture at any given age depends upon the hazard of death as well as the hazard of fracture over a defined interval (e.g., 10 years or lifetime). A major advantage of using fracture probability is that it standardises the output from the multiple techniques and sites used for assessment and also permits the presence or absence of risk factors other than BMD to be incorporated as a single metric. FRAX models are also calibrated to country-specific epidemiology.

The ability to compute fracture probabilities in individuals permits an estimate of the prevalence of high risk individuals within a given population where the population demography and the distribution of FRAX-based probabilities are known.

The aim of this score card element was to present the burden of osteoporosis in men and women in the EU27 countries expressed as the proportion of the population that has a 10 year probability of a major fracture (hip, spine, forearm or humerus) above a given threshold.

**Methods**

There is no international standard for defining high risk based on probabilities. In Europe, intervention thresholds are commonly defined as the 10-year probability of a major fracture that equals or exceeds that of a woman with a prior fragility fracture \[2, 3\], termed the probability fracture threshold. In North America threshold risks have been set at probabilities of 10 and 20 % \[4, 5\] and these were used for this assessment.

The majority of EU member states have a country-specific FRAX model. Where unavailable, a surrogate model was used. The distribution of FRAX probabilities in men and women was simulated in 5-year age intervals for each member state between the ages of 50 to 89 years \[6\] and applied to the demography of each country for 2010 \[7\]. Burden of disease was expressed as the number of men and women with a probability of major fracture above a threshold of 10 or 20 %. For comparative purposes, the burden was expressed as the proportion of the population aged 50--89 years with probabilities above these thresholds.

**Results**

Approximately 12.9 million men and women in the EU27 have a 10-year fracture probability that is 20 % or more. When a 10 % threshold is used the population at high risk rises to 41.3 million, representing respectively 3 and 8 % of the total EU population for 2010.

The proportion of the population aged 50 years or more that in 2010 had a fracture probability of 20 % or more varied among member EU states, ranging from 2 % in Romania to 17 % in Sweden (Table [11](#Tab11){ref-type="table"}). The proportion of the population aged 50 years or more that had a fracture probability of 10 % or more ranged from 12 % in Romania to 42 % in Sweden (Table [11](#Tab11){ref-type="table"}). Figure [9](#Fig9){ref-type="fig"} shows the rank order of population burden.Table 11Number of men and women (000) and proportion of the population aged 50--89 years (%) with a 10-year probability of a major fracture that exceeds 10 %, 20 % or the fracture threshold for womenCountryNumber of men and women (000)Proportion of population aged 50--89 years (%)\>20 %\>10 %\>Fracture threshold\>20 %\>10 %\>Fracture thresholdAustria4071,101325143711Belgium3551,05846092712Bulgaria5130833021112Cyprus20683662212Czech29392643182511Denmark377937214194811Estonia24926051913Finland10940222252011France1,6674,6382,71782112Germany2,4347,8403,77372412Greece3331,11052482713Hungary23884239372311Ireland11033914192811Italy2,0936,5922,86492812Latvia3915510251913Lithuania5320914151913Luxembourg13391882512Malta10351872312Netherlands22188168141512Poland3751,5671,54031212Portugal20065647951712Romania12776183421012Slovakia13952719783111Slovenia491697862310Spain6642,2841,94741512Sweden5671,437398174212UK1,9476,3102,41693011EU2712,91541,28321,339Fig. 9Proportion of men and women (%) aged 50--89 years with a 10-year probability of a major fracture that is 10 % or more and 20 % or more by member state

For completion, the table also shows the number of men and women that lie above a fracture threshold commonly used in assessment guidelines. This is considered later in relationship to the uptake of treatments in the EU27 (Chapter 4c).

**Score criteria**

Countries were ranked by tertiles of prevalence of the population aged 50--89 years above a 10 % probability threshold of a major osteoporotic fracture as given in Table [12](#Tab12){ref-type="table"}.Table 12Criteria for allocating scores

**Score allocation**

The proportion of the population (%) aged 50--89 years with a 10-year probability of a major fracture that is 10 % or more by member state is shown by category and rank in Fig. [10](#Fig10){ref-type="fig"}.Fig. 10The proportion of the population (%) aged 50--89 years with a 10-year probability of a major fracture that is 10 % or more by member state

**Comment**

The majority of EU member states have a country-specific FRAX model. For those countries where a country-specific FRAX model was unavailable, a surrogate model was used, based on the estimate that the epidemiology of hip fracture was similar. For Bulgaria, the Romanian model was used; for Cyprus, the Maltese model was used; for Estonia and Latvia, the Lithuanian model was used; for Luxembourg, the Belgian model was used; and for Slovenia, the Hungarian model was used.
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**1h Population projections**

**Domain**

Burden of disease---background information

**Background and aims**

Secular changes in life expectancy and birth rate are likely to increase the number of elderly individuals in the EU member states and thereby increase the need for resource allocation for diseases associated with ageing. The incidence of fragility fractures increases markedly with age, particularly in women. The aim of this background element is to estimate the increase in number of women aged 50 years or more in the EU member states.

**Methods**

The age and sex distribution of the EU member states was obtained from the UN for 2010 and 2025 using the medium variant \[1\].

**Results**

The population of women over 50 years is expected to increase by 22 % and in men by 17 % in the EU between 2010 and 2025. The number of men and women aged 50 years or more will increase in all countries except Bulgaria, Hungary and Latvia (Table [13](#Tab13){ref-type="table"}). In the remaining countries, the increment in the population varies widely.Table 13Projected percentage change in the male and female population between 2010 and 2025 according to category of age \[1\]CountryMen agedWomen aged50--74 years75+ years50--74 years75+ yearsAustria25572226Belgium18271713Bulgaria−1−1−311Cyprus36573163Czech Republic957437Denmark10701045Estonia621014Finland281141France17401722Germany13521023Greece23181718Hungary619−118Ireland37733853Italy25351821Latvia813−27Lithuania12369Luxembourg36644325Malta6100550Netherlands19751941Poland824721Portugal22311725Romania1461019Slovakia22381632Slovenia18601525Spain42333522Sweden1061935UK17461729

With some exceptions, the percentage increase in number of men and women aged 75 or more years is greater than that of the population aged 50--74 years. The exceptions include Belgium (women), Bulgaria (men), Greece (men), Lithuania (men), Luxembourg (women), Romania (men) and Spain (men and women).

For women over the age of 75 years, the change in the population ranged from less than 10 % in Latvia (7 %) and Lithuania (9 %) to more than 40 % in Cyprus, Denmark, Finland, Ireland, Malta and the Netherlands (Fig. [11](#Fig11){ref-type="fig"}).Fig. 11Projected increase by country in the female population aged 75 years or more (%) between 2010 and 2025 \[1\]

The increase in the male population aged over 75 years was generally more marked than in women. In men, the EU population aged 75 years or more is expected to increase by 33 %. In those countries with large expected changes in the proportion of the population aged 75 years or more, the increment is larger in men than in women (Fig. [12](#Fig12){ref-type="fig"}) since life expectancy, lower in men, is improving more rapidly in men than in women with time.Fig. 12The relation between the percentage increase in the male and female population aged 75 years or more in EU member states. The diagonal shows the line of identity

**Score criteria**

None---not a score card element

**Comment**

UN population projections over 15 years are relatively robust in that all men and women in 2025 aged 50 years or more had already attained adulthood in 2010. The projections expressed in relative change for countries with very small populations are uncertain (e.g. Malta, Cyprus) since population numbers are given by the UN rounded to the nearest 1000.
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**1i Fracture projections**

**Domain**

Burden of disease---scorecard element

**Background and aims**

As noted, the number of men and women aged 50 years or more is set to increase with time in the EU. The increase will be particularly marked in the elderly population. Since age is an important risk factor for fractures and the elderly population is projected to increase in the majority of member countries, the burden of fractures is also likely to increase.

The aim of this scorecard element was to estimate the increase in the annual number of fragility fractures from 2010 to 2025.

**Methods**

The incidence of hip fracture was determined from a systematic literature review \[1, 2\]. For other fractures, it was assumed that the age- and sex-specific incidence in relation to hip fracture followed that documented for Sweden \[3\] and other non-EU countries \[4\]. Outcomes included the three most common sites of osteoporotic fracture (hip, spine and forearm) as well as other fractures considered to be associated with osteoporosis (i.e. pelvis, rib, humerus, tibia, fibula, clavicle, scapula, sternum, and lower femur) \[3\]. For vertebral fractures, only those coming to clinical attention were included.

Fracture numbers were calculated from age- and sex-specific incidence and population sizes in 5-year age intervals for 2010 and 2025 \[5\]. It was assumed that the incidence of osteoporotic fractures did not change over time.

**Results**

The annual number of osteoporotic fractures in the EU27 will increase by 0.99 million from 3.49 million in 2010 to 4.48 million in 2025 (Table [14](#Tab14){ref-type="table"}). The increase in the annual number of fractures is found in all countries (Fig. [13](#Fig13){ref-type="fig"}), ranging from a 53 % increase in Ireland to a modest 4 % increase in Bulgaria. In 2025, Germany is expected to have the largest number of fractures with almost 940,000 fractures, followed by the UK with 680,000.Table 14Number of fractures in men and women in 2010 and number expected in 2025, and the percentage increase \[2\]CountryNumber of fractures 2010Number of fractures 2025∆ fractures 2010--2025 (number)∆ fractures 2010--2025 (%)Share of EU27 increaseAustria86,031115,68629,655343Belgium79,20198,52519,324242Bulgaria38,18439,6121,42940Cyprus5,0227,5362,514500Czech Republic75,35997,82922,470302Denmark66,06686,09420,028302Estonia8,67810,2081,530180Finland36,29248,93912,647351France378,082493,031114,9493012Germany732,137936,461204,3242821Greece84,256105,28421,028252Hungary90,011101,54411,533131Ireland17,94727,3729,425531Italy466,475599,034132,5592813Latvia14,28416,2041,920130Lithuania15,08417,4842,400160Luxembourg2,6844,0151,331500Malta2,6183,7441,125430Netherlands76,691107,67130,980403Poland167,033208,59141,558254Portugal51,32968,44817,119332Romania94,240110,09915,858172Slovakia38,36349,50811,145291Slovenia15,47121,7956,323411Spain203,794285,45381,659408Sweden106,857135,02928,172263UK535,724681,956146,2312715EU273,487,9144,477,152989,23828100Fig. 13The percentage increase in the number of fragility fractures between 2010 and 2025 in the EU and its member states \[2\]

**Score criteria**

Countries were ranked by the percentage increase in the annual number of fractures in men and women between 2010 and 2025 as shown in Table [15](#Tab15){ref-type="table"}.Table 15Criteria for allocating scores

**Score allocation**

The percentage increase in the annual number of fractures in men and women between 2010 and 2025 is shown by category and rank in Fig. [13](#Fig13){ref-type="fig"}.

**Comment**

The analysis assumes that the age- and sex-specific incidence of fractures did not change over the 15-year time interval. Secular trends in fracture risk are ill-documented with the exception of hip fracture \[6\] where limited information is available. In general, age- and sex-adjusted hip fracture incidence increased until the mid or end of the 20th century, with a subsequent plateau or even a small decrease \[6\]. In Europe, this tendency is best documented for Sweden, Finland, Spain, Germany, Netherlands and Hungary.

Countries with substantial increases in the number of fractures need to take this into account for future healthcare planning.
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**Chapter 2 Policy framework**

**2a Quality of existing information**

**Domain**

Policy framework---scorecard element

**Background and aims**

Fracture incidence is poorly documented in the EU \[1\]. The fracture that has been best evaluated is hip fracture. Hip fractures account for the majority of health care expenditure, mortality and morbidity and can be used as a proxy for osteoporosis. The EU comprises countries with some of the highest hip fracture rates worldwide \[2\], but documentation of the size of the problem and the quality of data vary between countries.

Documentation of the burden of disease is an essential prerequisite to determine the resources that should be allocated to the diagnosis and treatment of the disorder. It also provides information concerning the priority a disease should be awarded by healthcare policy makers. A fracture registry is a centralised database collecting the number of individual fractures per person, per year within a population and is used for research and resource allocation. The data collected can also be used to identify high-risk patients in need of further prevention programs. The main objective of this scorecard element is to provide an integrated estimate of the quality of current documentation on the burden of osteoporosis fractures in the countries of the European Union.

**Methods**

Published information on hip fracture incidence was obtained by systematic review, in some cases through contact with Ministries of Health \[2\]. Available studies in each country were reviewed for quality and representativeness of the country. Epidemiology of other fractures was obtained by systematic review \[1\].

Data on national or regional fracture registers \[3\] were updated by an IOF questionnaire to the EU Osteoporosis Consultation Panel.

The quality of the available information was scored, with the presence of an established national fracture register as the highest grade. In the absence of a fracture register, an intermediate score was dependent on the presence of good quality national hip fracture rates.

**Results**

High quality national data on hip fracture rates were identified in 15 member states (Table [16](#Tab16){ref-type="table"}). Fair to poor quality national estimates were found for Lithuania and Slovenia. No data were available for four countries (Bulgaria, Cyprus, Latvia, and Luxembourg). In the remaining six countries, regional estimates of variable quality were identified. Most index years included data from 2000 onwards.Table 16Characteristics of information available on fracture rates in the European UnionIncidence of hip fractureEstablished National Fracture RegistriesScoreQuality^a^Sample^b^PresentData^c^AustriaGNNo^d^3BelgiumGNYesHip3BulgariaNo0CyprusNo0Czech RepublicGNNo2DenmarkGNYesHip+3EstoniaPRNo1FinlandGNYesHip+3FranceGNNo^d^2GermanyGNYesHip+3GreeceP/F/GRNo1HungaryGNYesHip+3IrelandGNYesHip3ItalyGNNo^d^Hip+2LatviaRYesHip+3LithuaniaFRNo1LuxembourgNo0MaltaGNNo2NetherlandsGNYesHip+3PolandFRNo1PortugalGNYesHip+3RomaniaGNNo2SlovakiaGNYesHip+3SloveniaFNNo2SpainF/GRNo^d^Hip+1SwedenGRYesHip3UKGRYesHip3Responses derived from questionnaire to National Societies^a^Quality: *G* good; *F* fair; *P* poor \[2\]^b^Catchment: *N* national; *R* regional^c^ *Hip* Registration of hip fracture only. *Hip+* Registration of hip and other fracture outcomes^d^Regional registers available

Data on the incidence of clinical vertebral fractures are lacking in most of the countries in the EU, the exceptions being regional data for Sweden and the UK. In the UK, the incidence of clinically identified fractures has been studied within the General Practice Research Database (GPRD). The incidence is, however, very low and it is likely that the majority of fractures were not coded.

Information on forearm fracture is also scarce. Forearm fractures are treated in hospital outpatient departments. There are reports from EU27 countries on the incidence of forearm fractures that lead to hospitalisation, e.g. from France and Italy, but these are of limited value. There are also studies published from Slovenia and Italy which present incidence of forearm fractures treated both in inpatient and outpatient care. However, the Slovenian study only reports fractures occurring in women, and the Italian study lacks age stratification of data within the elderly population. Credible data are only available for Hungary, the UK and Sweden \[1\].

National fracture registries were in place in 12 of the EU countries (Table [16](#Tab16){ref-type="table"}). The majority of these acquire information on all or several fracture outcomes (Austria, Denmark, Finland, Germany, Hungary, Ireland, Latvia, Netherlands, Portugal and Slovakia) and the remainder registered hip fracture alone (Belgium, Ireland, Sweden and UK). In several additional countries, local registers are available.

**Score criteria**

The presence of an established national fracture register was allocated the highest grade. In the absence of a fracture register, an intermediate score was given with the availability of good quality national hip fracture rates. Criteria for allocating scores are given in Table [17](#Tab17){ref-type="table"}.Table 17Criteria for allocating scores

**Score allocation**

Countries, ranked and categorised by score, are shown in Fig. [14](#Fig14){ref-type="fig"}.Fig. 14Quality of information available on the epidemiology of hip fractures in the EU \[IOF audit\]

**Comments**

The quality of this information is limited. Firstly, it is based on responses to a questionnaire to national societies and not to government agencies. Secondly, centralised data are not necessarily equivalent to a national registry.

**References**
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**2b National health priority**

**Domain**

Policy framework---scorecard element

**Background and aims**

Data from the Global Burden of Disease 2010 Study indicate that musculoskeletal disorders are the second greatest cause of disability as measured by years lived with disability (YLD), worldwide and across most regions of the world \[1\]. In terms of both death and disability, musculoskeletal diseases are the non-communicable diseases that have the fourth greatest impact on the health of the world population (6.8 %). They closely follow cardiovascular and circulatory diseases (11.8 %), tumours (7.7 %), and mental/behavioural disorders (7.4 %) \[2\]. Disability due to musculoskeletal disorders has increased by 45 % from 1990 to 2010 compared to a 33 % average across all other disease areas. These data suggest that musculoskeletal disease merits a high priority in health care policy. Osteoporotic fractures in Europe accounted for more disability-adjusted life years lost (2,006,000 DALYs) than rheumatoid arthritis (1,048,000) but less than that for osteoarthritis (3,088,000) representing 33 % of the DALYs of these disorders \[3\].

When a disease becomes a National Health Priority (NHP), it is usually mandated by a government body/ministry of health or another official institution. Osteoporosis may be a designated NHP on its own, or it may be included as part of a musculoskeletal diseases NHP. The development of a national action plan, clear objectives and support for education and awareness programs also often result from a NHP mandate. The aim of this scorecard element was to determine the extent to which member states have recognised this need.

**Methods**

Information on NHP \[4\] was updated by an IOF questionnaire to the EU Osteoporosis Consultation Panel undertaken in December 2012.

Respondents were asked whether osteoporosis or musculoskeletal diseases were officially documented as a NHP in each member state and to provide the documentary evidence. Further questions related to action plans linked to the NHP and their implementation.

**Results**

The majority of member states (18/27) do not recognise osteoporosis or musculoskeletal diseases as a NHP (Table [18](#Tab18){ref-type="table"}). Of those member states that have developed a NHP, the focus has been on nutrition (six countries), falls prevention (four countries), exercise (four countries), and the institution of fracture liaison services (two countries). Action plans have been implemented in Bulgaria, Luxembourg and Romania. There is scant evidence for the implementation of action plans in Finland, France, Italy and Portugal. In Sweden, osteoporosis has only recently become a NFP (2012). In the UK, implementation is indirect via the establishment of quality indicators in the audit of primary care practice (see Chapter 3h).Table 18Countries in which osteoporosis or musculoskeletal diseases were officially documented as a NHP, its scope and action plansNHP and dateGovernment supportScope^a^Action planScoreAustriaNo--1BelgiumNo--1BulgariaYes 2006YesN, FLSYes3CyprusNo1Czech RepublicNo1DenmarkNo1EstoniaNo1FinlandYesYesN, E, FNo2FranceYes 2004YesN, E, FNo2GermanyNo1GreeceNo1HungaryNo--1IrelandNo1ItalyYes 2005YesN, FUncertain2LatviaNo1LithuaniaNo1LuxembourgYesYesN, E, FYes3MaltaNo1NetherlandsNo1PolandNo1PortugalYes 2004YesPRarely implemented2RomaniaYesYesCase findingYes3SlovakiaNo1SloveniaNo1SpainNo1SwedenYes 2012YesNot yet definedNo2UKYes 2009YesNE, FLSIndirect3Responses derived from questionnaire to National Societies^a^ *N, E, F* Nutrition, Exercise, Falls prevention; *P* professional education; *FLS* Fracture liaison services

**Score criteria**

The presence of government-backed NHP with an implemented action plan was allocated the highest grade. In the absence of an action plan, an intermediate score was given. Criteria for allocating scores are given in Table [19](#Tab19){ref-type="table"}.Table 19Criteria for allocating scores

**Score allocation**

Countries, ranked and categorised by score, are shown in Fig. [15](#Fig15){ref-type="fig"}.Fig. 15Categorisation of EU countries according to the existence of government-backed NHP for osteoporosis or musculoskeletal diseases \[IOF audit\]

**Comment**

Unless osteoporosis prevention and treatment become a priority for governments and health care providers, the growing number of osteoporotic fractures will have a serious impact on society---not just in terms of people's quality of life, but also because of increased costs incurred for acute healthcare, rehabilitation and nursing care.
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**2c Who manages osteoporosis?**

**Domain**

Policy framework---scorecard element

**Background and aims**

In 2010, it is estimated that 22 million women and 5.5 million men in the EU had osteoporosis using the diagnostic criterion of the WHO \[1\]. In 2010, the number of new osteoporosis-related fractures in the EU was estimated at 3.5 million, comprising approximately 610,000 hip fractures, 520,000 vertebral fractures, 560,000 forearm fractures and 1,800,000 other fractures (i.e. pelvis, rib, humerus, tibia, fibula, clavicle, scapula, sternum, and other femoral fractures). Osteoporosis is a common disease and effective treatments are widely available. As such, in most health care systems the vast majority of patients with osteoporosis is preferably managed at the primary health care level by general practitioners with specialist referral reserved for difficult cases, for example men and individuals in whom a secondary cause of osteoporosis is suspected.

The aim of this element was to determine whether the care of osteoporosis was primarily devolved to primary care physicians (GPs, family doctors). If not, then the lead specialty was asked for. The training of specialists is considered in Chapter 2d.

**Methods**

Data were acquired by an IOF questionnaire to the EU Osteoporosis Consultation Panel undertaken in December 2012. Respondents were asked whether osteoporosis was primarily devolved to primary care physicians (GPs, family doctors). If not, the single specialty that looked after most cases of osteoporosis was asked. In the case where there was near equality between two or more specialties, they were each recorded.

**Results**

Primary care was the principal provider of the medical care of osteoporosis in 15 of the 27 EU member states (Table [20](#Tab20){ref-type="table"}). In the remainder, the principal care was provided by hospital specialists. In Greece and Hungary, a single hospital specialty was the dominant provider (orthopaedics and rheumatology, respectively). In the remaining countries, the care of osteoporosis was split between disciplines. The number of disciplines was usually two (Bulgaria, Czech Republic, Denmark, Germany, Italy and Romania) but was three in the case of Ireland and Slovakia, and four or more for Malta, Poland and Sweden. The specialties involved comprised rheumatology (noted 10 times), endocrinology (9), orthopaedics (5), geriatrics (3), clinical osteology (2), internal medicine (2) gynaecology (1) and rehabilitation medicine (1). The panel were concerned by the multiplicity of specialists that had a primary role in the care pathway of patients in some countries and viewed this as an impediment to consistent care.Table 20Care pathway for patients with osteoporosis by countryPrimarily devolved to primary careLead specialtyScoreAustriayes3Belgiumyes3BulgarianoRheumatology, endocrinology1Cyprusyes3Czech RepublicnoClinical osteology, endocrinology1DenmarknoRheumatology, endocrinology1Estoniayes3Finlandyes3Franceyes3GermanynoOrthopaedics, clinical osteologyGreecenoOrthopaedics2HungarynoRheumatology2IrelandnoRheumatology, endocrinology, geriatrics1ItalynoRheumatology, endocrinology1Latviayes3Lithuaniayes3Luxemburgyes3MaltanoRheumatology, gynaecology, endocrinology, geriatrics1Netherlandsyes3PolandnoRheumatology, orthopaedics, rehabilitation medicine, internal medicine1Portugalyes3RomanianoRheumatology, endocrinology1SlovakianoRheumatology, orthopaedics, endocrinology1Sloveniayes3Spainyes3SwedenyesRheumatology, orthopaedics, endocrinology, internal medicine, geriatrics3UKyes3Responses derived from questionnaire to National Societies

**Score criteria**

Where the care of osteoporosis was primarily devolved to primary care physicians (GPs, family doctors), this was allocated the highest grade. If not, then an intermediate score was given where osteoporosis is mainly managed by a single specialty, as given in Table [21](#Tab21){ref-type="table"}.Table 21Criteria for allocating scores

**Score allocation**

Countries, ranked and categorised by score, are shown in Fig. [16](#Fig16){ref-type="fig"}.Fig. 16Patterns of principal care of patients with osteoporosis \[IOF audit\]. \*See comment below

**Comment**

Care management pathways are not necessarily divided by primary care and specialty care. The panel supports the view that long-term management should preferably be undertaken by GPs, contingent on adequate training, but there is a specialist role in initial evaluation, particularly in the context of fracture liaison services (see Chapter 3g). In Germany, there is the opportunity for specialists in many disciplines to be specially trained and accredited in the primary care of patients with osteoporosis. These considerations should temper the interpretation of the scores allocated.

**Reference**
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**2d Is osteoporosis a component of specialty training?**

**Domain**

Policy framework---scorecard element

**Background and aims**

The large number of men and women who suffer the consequences of osteoporosis raises the question of whether there is adequate training of medical practitioners in this specialty and, indeed, which specialty takes a leadership role.

The aim of this background element was to determine whether osteoporosis and metabolic bone disease are a recognised specialty or recognised component of specialty training.

**Methods**

Data were acquired by an IOF questionnaire to the EU Osteoporosis Consultation Panel undertaken in December 2012. Information requested included whether osteoporosis or metabolic bone disease is a recognised medical specialty in each country. Also asked was whether osteoporosis or metabolic bone disease is a recognised component of specialty medical training and, finally, which specialists took lead roles in the care of osteoporosis.

The available information was scored, with the presence of an established specialty as the highest grade. In the absence of osteoporosis or metabolic bone disease being a recognised medical specialty, an intermediate score was dependent on the disorder being a recognised component of specialty medical training.

**Results**

Osteoporosis and metabolic bone disease is a recognised specialty in only four of the EU member states (Czech Republic, Denmark, Estonia and Lithuania). In some countries, there are specialists that deal exclusively with metabolic bone diseases (e.g. the UK) most usually in an academic setting. The more usual finding is that the specialty care of osteoporosis is via another specialty (Table [22](#Tab22){ref-type="table"}). The specialties involved include endocrinology, geriatrics, gynaecology, internal medicine, orthopaedic surgery, rehabilitation medicine and rheumatology. In the majority of countries, osteoporosis or metabolic bone disease is a recognised component of specialty medical training but there is no information on the extent to which this is taken advantage of. In Germany, a postgraduate training in clinical osteology is available to specialists from different disciplines to become certified. In two countries (Ireland and Poland) osteoporosis was neither an accepted medical specialty nor a component of specialty medical training. In the UK, experience in metabolic bone disease may form a component of specialist training but is not mandatory.Table 22Specialists caring for osteoporosis (OP)OP recognised as a specialtyLead specialists^a^OP recognised as a component of specialty trainingScoreAustriaNoRh, Orth, Gyn, Endo, IntYes2BelgiumNoRh, Gyn, Endo, Ger, Rehab, IntYes2BulgariaNoOrth, Gyn, IntYes2CyprusNoRh, Orth, Gyn, Endo, IntYes2Czech RepublicYesRh, Orth, Gyn, Endo, IntYes3DenmarkYesGerYes3EstoniaYesOrth, Endo, RhYes3FinlandNoRh, Orth, Gyn, Endo, Ger, Rehab, IntYes2FranceNoRh, Gyn, Endo, GerYes2GermanyNoRh, Orth, Gyn, Endo, Ger, Rehab, IntYes2GreeceNoRh, Gyn, EndoYes2HungaryNoRh, Orth, Gyn, Endo,Rehab, IntYes2IrelandNoRh, Gyn, Endo, Ger, RehabNo1ItalyNoRh, Endo, Ger, Rehab, IntYes2LatviaNoRh, Endo, IntYes2LithuaniaYesRh, Orth, Endo, Ger, Rehab, IntYes3LuxembourgNoRh, Orth, Gyn, Endo, Ger, Rehab, IntYes2MaltaNoRh Orth, Gyn, Endo,Rehab, IntYes2NetherlandsNoRh, Orth, Endo, Ger, IntYes2PolandNoRh, Orth, Endo,No1PortugalNoRh, Orth, Gyn, Endo, Ger, RehabYes2RomaniaNoOrth, RehabYes2SlovakiaNoGynYes2SloveniaNoRh, Gyn, Endo,RehabYes2SpainNoRh, Orth, Gyn, Endo, Ger, Rehab, IntYes2SwedenNoRh, Orth, Endo, IntYes2UKNoRh, Orth, Endo, Ger, GynYes2Responses derived from questionnaire to National Societies^a^ *Endo* endocrinology, *Ger* geriatrics, *Gyn* gynaecology, *Int* internal medicine, *Orth* orthopaedic surgery, *Rehab* rehabilitation medicine, *Rh* rheumatology

With the exception of Slovakia, the lead specialties are multiple. In some countries, all seven specialties took what were considered lead roles in the management of osteoporosis. This clearly indicates that there is no dominant specialty that looks after osteoporosis in any one country and a great diversity between countries. The specialty representation is illustrated in Fig. [17](#Fig17){ref-type="fig"}.Fig. 17The specialty representation in the EU countries. Note that more than one specialty per country can be represented (see Table [22](#Tab22){ref-type="table"}) \[IOF audit\]

**Score criteria**

The highest score was allocated to a country if osteoporosis or metabolic bone disease was an established specialty. In the absence of osteoporosis or metabolic bone disease being a recognised medical specialty, an intermediate score was dependent on the disorder being recognised component of specialty medical training (Table [23](#Tab23){ref-type="table"}).Table 23Criteria for allocating scores

**Score allocation**

The score allocation and grade for each country is shown in Fig. [18](#Fig18){ref-type="fig"}.Fig. 18The score allocation and grade for specialist training in each country \[IOF\]

**Comment**

There is a wide variation in the specialties which cater for osteoporosis. Although it is possible that these specialties educate their trainees adequately, the wide variation may be reflected in inconsistent patient care, training of primary care physicians and a suboptimal voice to "defend" the interests of osteoporosis.

**2e National Societies**

**Domain**

Policy framework---scorecard element

**Background and aims**

The role of national patient societies is to improve the care of patients and increase awareness and prevention of osteoporosis and related fractures among the general public. In addition to their role in patient and public outreach, the societies provide practical and unbiased information for osteoporosis patients and their families through telephone help lines, local self-help groups and information events, media outreach, general educational activities and by distributing information via brochures and their websites. The patient societies often work closely with clinical and research associations to disseminate information about new treatments and patient guidelines. Finally, with their often large and active membership base, societies play an important role in advocacy by calling for access to timely and affordable diagnosis and treatment. This is particularly necessary for osteoporosis which, as a chronic 'silent' disease, is too often neglected by health authorities.

**Methods**

Data were acquired from the International Osteoporosis Foundation on the patient-contact societies operating in the European Union. Support societies fall into three categories: those primarily involved with direct patient contact (e.g. a help line), societies that are patient-orientated but without patient contact and scientific societies that have no outreach to patients. A high score was allocated to those countries with a patient-contact/support society. In its absence, an intermediate grade was allocated to patient-orientated societies and the lowest score to countries with scientific societies and no patient outreach.

**Results**

The individual societies are listed in the acknowledgements. The distribution of type of society and number by member state is shown in Table [24](#Tab24){ref-type="table"}. Eight countries had a patient-contact society. For patient-orientated societies, there were 26 societies in 18 member states. There were 49 scientific societies in 26 member states (the exception was Ireland).Table 24The number and type of osteoporosis societies in the EU member states \[IOF Audit\]Patient contactPatient orientatedScientificScoreAustria1133Belgium1--13Bulgaria--222Cyprus--112Czech Republic--122Denmark--112Estonia----11Finland--112France--232Germany4233Greece--132Hungary--112Ireland1----3Italy1443Latvia1--13Lithuania--122Luxemburg----11Malta----11Netherlands--112Poland--132Portugal--122Romania--132Slovakia----21Slovenia1--13Spain--232Sweden1123UK1--13EU278/2718/2726/27

**Score criteria**

Support societies was categorised by patient contact (Table [25](#Tab25){ref-type="table"}). A high score was allocated to those countries with a patient-contact society. In its absence, an intermediate grade was allocated to patient-orientated societies and the lowest score to countries with scientific societies and no patient outreach.Table 25Criteria for allocating scores

**Score allocation**

The score for each country by score and rank is shown in Fig. [19](#Fig19){ref-type="fig"}.Fig. 19Society support to osteoporosis by score \[IOF audit\]

**Comment**

The score is based on the audit by the IOF of its affiliated societies. As such, it necessarily did not consider societies that are not members of the IOF Committee of National Societies. This consideration should temper the interpretation of this element.

**Chapter 3. Service provision**

**3a Treatments for osteoporosis**

**Domain**

Service provision---scorecard element

**Background and aims**

A wide variety of approved drug treatments is available for the management of osteoporosis. Potential limitations of their use in member states relate to reimbursement policies which may impair the delivery of health care.

The aim of this scorecard element was to review the provision of medical intervention in each member state and, in particular, to determine whether restricted reimbursement was considered an obstacle to the accessibility and long-term uptake of interventions.

**Methods**

Information on access to treatment \[1\] was updated by an IOF questionnaire to the EU Osteoporosis Consultation Panel undertaken in December 2012. Information requested included the treatments that are currently reimbursed, the level of reimbursement, the conditions on which reimbursement are offered and whether reimbursement policy interferes with what patients could accept or physicians in each country would wish to recommend to patients. We additionally asked whether there are designated first-line treatments in each country.

The following interventions were included: the bisphosphonates (alendronate, ibandronate, risedronate and zoledronic acid), raloxifene, denosumab, strontium ranelate, parathyroid hormone derivatives (PTH and teriparatide) and vitamin D analogues (alfacalcidol and calcitriol). We excluded gonadal steroids (prescribed for hypogonadal states rather than for osteoporosis) and calcium/vitamin D products (most usually available without prescription).

Costs for first- and second-line treatment per year (weighted on price and market share in each country) were taken from Hernlund \[2\].

The available information was scored on the basis of full or partial reimbursement. In those countries with restricted reimbursement, countries were identified where reimbursement policy interfered with what patients could accept or physicians would wish to recommend to patients.

**Results**

Most interventions were reimbursed in most countries. Full reimbursement was provided in only 7 of 26 EU member states (Table 26). In the remaining countries, the level of reimbursement ranged from 0 (Malta) to up to 100 % for selected treatments (Luxembourg and Spain). Restricted reimbursement was reported as a significant obstacle to accessibility and long-term uptake in several countries. Examples include unaffordable cost to the patient (Spain), age restrictions for some agents (Belgium, Italy, Poland), less reimbursement in the absence of a prior fracture (Estonia), and reimbursement for some or all agents conditional on a specialist referral (Czech Republic, Greece and Hungary).

In several countries, reimbursement was conditional on clinical criteria, which prevented health care professionals from prescribing some or all agents to individuals at high risk. Examples include reimbursement criteria based on BMD alone (i.e. irrespective of prior fractures in osteopenic cases) (Bulgaria, Lithuania, Romania), patients at high risk identified by FRAX (Belgium). In France, the intricacies of reimbursement are considered as too complicated by GPs so that many have lost interest in managing the disease. As might be expected, impedimenta were less frequent in those countries with full reimbursement (7/8) than in those with incomplete reimbursement (10/19).

First-line drugs were mandated in 18 of 29 countries. The majority comprised the oral bisphosphonates and, in particular generic alendronate.

As expected, the average cost of intervention (weighted on price and market share in each country) varied markedly and ranged from € 160 (Belgium) to € 1269 (Demark). There was similar price inequality for generic alendronate (Table [26](#Tab26){ref-type="table"}).Table 26Levels of reimbursement, reported barriers to care from reimbursement policies and costs of treatment \[IOF audit\]Reimbursed (%)Patient or professional impedimentFirst-line drugs identifiedAverage cost (€/year)Generic alendronate (€/year)Austria100NoYes257174Belgium10--20YesYes160123Bulgaria25YesNo17980Cyprus100^a^NoNo640327Czech Republic50--90NoYes359187Denmark50--90NoYes1269126Estonia50--90YesNo232171Finland40NoYes20540France30--65YesYes412209Germany100NoYes619245GreecePartYesNo391239Hungary70--90YesYes354115Ireland100^a^NoNo570240Italy100YesNo619294Latvia50Nonr30885Lithuania50--80YesYes409146Luxembourg80--100NoNo336109Malta0NoYes545190Netherlands100NoYes2264Poland30YesNo581245Portugal69NoYes31316Romania50YesYes17353Slovakia90+NoYes40116Slovenia100NoYes234161Spain50--100YesYes478201Sweden100NoYes66727UK100NoYes22613^a^Depending on income; *nr* not recorded;

In several countries, some registered treatments were not reimbursed which are listed by treatment in Table [27](#Tab27){ref-type="table"}.Table 27Registered treatments that are not reimbursed \[2\]TreatmentCountries where reimbursement is not offered for osteoporosisRisedronateEstonia, MaltaAlendronateMaltaIbandronateMalta, Poland, SwedenZoledronic acidEstonia, Malta, Poland, RomaniaRaloxifeneBulgaria, Latvia, Malta, PolandDenosumabEstonia, France, Malta, Portugal, RomaniaStrontium RanelateMalta, PolandTeriparatide and PTH (1--84)Bulgaria, Estonia, Luxembourg, Malta, Netherlands, Poland, RomaniaAlfacalcidol/calcitriolBelgium, Denmark, France, Ireland, Poland

**Score criteria**

The highest score was allocated for full reimbursement. In those countries with restricted reimbursement, countries were identified where reimbursement policy interfered with what patients could accept or physicians would wish to recommend to patients. Categories are shown in Table [28](#Tab28){ref-type="table"}.Table 28Criteria for allocating scores

**Score allocation**

Countries, ranked and categorised by score, are shown in Fig. [20](#Fig20){ref-type="fig"}.Fig. 20Ranking and score for access to medical intervention \[IOF audit\]. \*See comment below \[IOF audit\]

**Comment**

Note that full reimbursement does not necessarily denote full access to treatment. For example, in Germany and the UK, the availability of drugs other than generic alendronate is restricted, sometimes severely so, by regional or local budgetary policies.

The large price range of generic alendronate (€4 to €294 per year) is remarkable as an index of inequality of provision within the EU.
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**3b Availability of DXA**

**Domain**

Service provision---scorecard element

**Background and aims**

The assessment of bone mass forms a cornerstone for the general management of osteoporosis being used for diagnosis, risk prediction, selection of patients for treatment and monitoring of patients on treatment. The appropriate sites and technology are measurement at the lumbar spine and hip with dual-energy X-ray absorptiometry (DXA). The capacity to service these needs depends therefore on the availability of equipment.

The aim of this score card element was to compare the availability of DXA in the EU member states.

**Methods**

An estimate of the number of operational DXA machines was determined from the combined sales information of the three major providers (GE Lunar, Hologic and Norland) provided in confidence to the IOF \[1\]. The metric for each country was the number of DXA units/million of the general population.

**Results**

The number of DXA units expressed per million of the general population varied markedly in the EU (Table [29](#Tab29){ref-type="table"}). Belgium, Greece and France were the most well provided for and Bulgaria, Luxembourg and Romania the least. Previous surveys have indicated a marked heterogeneity in the availability of DXA in the EU \[2--4\] and the present survey, based on manufacturer sales, confirms this finding (Fig. [21](#Fig21){ref-type="fig"}).Table 29The number of central DXA units available in the EU27 per million of the general population \[1\]CountryDXA units/millionCountryDXA units/millionCountryDXA units/millionAustria28.7Germany21.1Netherlands10.7Belgium53Greece37.5Poland4.3Bulgaria1.2Hungary6.0Portugal26.9Cyprus23.9Ireland10.0Romania2.4Czech Republic5.2Italy18.6Slovakia10.7Denmark14.6Latvia4.9Slovenia27.1Estonia8.9Lithuania3.4Spain8.4Finland16.8Luxemburg2.0Sweden10.0France29.1Malta9.7UK8.2Fig. 21DXA units/million of the general population in 2010 based on sales of DXA in the EU supplied by manufacturers \[1\]. The horizontal line denotes a minimum service requirement \[2\]

**Score criteria**

The score was based on the number of DXA units/million of the general population categorised by tertiles given in Table [30](#Tab30){ref-type="table"}.Table 30Criteria for allocating scores

**Score allocation**

Countries, ranked and categorised by score, are shown in Fig. [21](#Fig21){ref-type="fig"}.

**Comment**

The requirement for assessing and monitoring the treatment of osteoporosis to implement practice guidelines has been estimated at approximately 11 DXA units per million of the general population \[2\]. The survey indicated that about 50 % of countries in the EU had the recommended number of DXA machines for their population. It is important to note that the figures provided do not distinguish between machines dedicated in part or in full to clinical research, and those that lie idle or are underutilised because of lack of funding. It is likely, therefore, that a majority of countries are under-resourced in the context of their practice guidelines.

The granularity of the data means that it is not possible to determine the use of DXA equipment (for research or service), the efficiency and quality of service or the extent of inequity of geographic distribution of DXA machines.
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**3c Access to DXA**

**Domain**

Service provision---Scorecard element

**Background and aims**

The assessment of osteoporosis does not solely depend on the availability of bone mass measurements at the lumbar spine and hip with dual-energy X-ray absorptiometry (DXA) (see chapter 3b). Access also depends upon the efficiency with which the technology is used, the ease of patient access (e.g. travelling time), regulatory constraints and barriers to reimbursement.

The aim of this background element was to compare the access to DXA in the EU member states.

**Methods**

Data were acquired by means of an IOF questionnaire sent to the EU Osteoporosis Consultation Panel undertaken in December 2012. Respondents were asked to update previous estimates for the cost, waiting time and reimbursement for DXA. Where information was lacking, data for waiting times and reimbursement were taken from the 2008 IOF EU audit or the Eastern European and Central Asian Audit \[1, 2\]. Respondents were specifically invited to comment on whether the reimbursement policy (or lack of reimbursement) provided barriers to the physician's assessment of patients.

**Results**

The average waiting time for DXA ranged from 0 (Bulgaria and Germany) to 140 days (Ireland) (Table [31](#Tab31){ref-type="table"} and Fig. [22](#Fig22){ref-type="fig"}). There was no clear relation between waiting times and the availability of DXA (see chapter 3b). For example, the average waiting time in Italy was reported to be 83 days, though the number of DXA machines is high (18.6 machines/million of the general population). This disparity arises because many of DXA units lie in research centres or the private sector and are unavailable to the majority of the population. Conversely, there is no waiting time in Bulgaria where the provision of DXA is low (1.2 DXA units/million). The latter observation reflects the fact that the few machines available are only used to service specialised departments and that BMD assessments are unavailable to the vast majority of the population at risk. Thus, a disparity between the availability of equipment and waiting time identifies a high heterogeneity in the use of BMD to assess osteoporosis. A further consideration is the uneven geographical location of equipment, which is known to be problematic in Italy, Spain and the UK.Table 31Cost and reimbursement of DXA \[IOF audit\]CountryWaiting time (d)Cost (€)ReimbursementBarriers to clinical practiceAustria1435YesFor some indications and \<65 yearsBelgium1442.5^a^PartialYes, in case of rather low-risk profileBulgaria037.5^a^NoneDepends on incomeCyprus2070Yes (depending on income)n.r.Czech Republic40^a^25YesFor some indicationsDenmark^b^3035YesNoEstonia1417Yesn.r.Finland1105^a^YesNoFrance1440Yes (conditional)Dependent on clinical risk factors. Algorithm is considered as too complicated for most GPsGermany045YesReimbursed only after fractureGreece^b^11^a^52YesNoHungary15^a^30YesReimbursed only for womenIreland140^a\ b^100Yes (conditional)Reimbursed if privately insured. Otherwise, depending on incomeItaly83^a^50^a^Yes (conditional)For some indicationsLatvia10^a^23.5^a^YesNoLithuania6^a^21.5^a^NoNoLuxembourg3035^a^YesNoMalta105^a^184^b^YesFor some indicationsNetherlands14^a^105YesNoPoland120^a^Yes (conditional)Reimbursement only if seen by specialistsPortugal850^a^YesNoRomania722.5^a^YesYesSlovakia18^a^30YesNoSlovenia11^a^40Yes (conditional)Reimbursement only for secondary osteoporosisSpain105^a^41^a^YesNoSweden6090YesNoUK11^a^99YesYes*n.r.* Data not recorded^a^Average of range^b^Data from \[1\]Fig. 22Reported average waiting time for a DXA assessment by EU country \[IOF audit\]

Reimbursement for DXA scans varied widely between member states both in terms of the criteria required and level of reimbursement awarded, and a majority of countries provided full reimbursement (Table 31). In others, reimbursement or partial reimbursement was limited and usually dependent on physician referral for approved indications, sometimes restricted to criteria that did not satisfy the requirements of good clinical practice. An example is seen in Bulgaria (and incidentally in Switzerland) where reimbursement is only offered if the BMD test turns out to be positive (i.e. shows osteoporosis). Other examples of restricted access included reimbursement only for limited indications (Austria, Czech Republic, Malta and Slovenia), only if seen by a specialist (Poland), only for women (Hungary) and only after fracture (Germany).

The cost of DXA also varied widely (Table 31) and bore little relation to the wealth of the nation or to the availability of DXA machines.

**Score criteria**

The highest score was allocated for unconditional reimbursement. In those countries with restricted reimbursement, countries were identified where reimbursement interfered with what patients could accept or physicians would wish to recommend to patients. Categories are shown in Table 32.Table 32Criteria for allocating scores

**Score allocation**

Countries, ranked and categorised by score, are shown in Fig. [23](#Fig23){ref-type="fig"}.Fig. 23Categorisation of access to DXA by score in the EU27 \[IOF audit\]

**Comment**

There is a remarkable disparity between the availability of equipment and waiting time, which reflects a high heterogeneity in the use of BMD to assess osteoporosis. Unimpeded access to DXA is confined to a minority of member states.
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**3d Access to risk assessment algorithms**

**Domain**

Service provision---scorecard element

**Background and aims**

The effective targeting of treatment to those at highest risk of fracture requires an assessment of fracture risk. Historically, the targeting of treatment became feasible with the advent of bone mineral density measurements. The causation of fragility fractures is, however, heterogeneous and many additional factors have been identified that contribute to fracture risk. In turn, this has led to the development of risk algorithms that can enhance the assessment of fracture risk to better target interventions, particularly in primary care.

There are several assessment tools available in Europe \[1--5\]. The most widely used is FRAX®. FRAX is a computer-based algorithm (<http://www.shef.ac.uk/FRAX>) that calculates the 10-year probability of a major fracture (hip, clinical spine, humerus or wrist fracture) and the 10-year probability of hip fracture. Fracture risk is calculated from age, body mass index and well validated dichotomized risk factors. Femoral neck bone mineral density (BMD) can be optionally input to enhance fracture risk prediction. Fracture probability differs markedly in different regions of the world so that FRAX is calibrated to those countries where the epidemiology of fracture and death is known (currently 50 countries). In addition to the web site, FRAX has been incorporated into the software of densitometers and is available as an application for the iPhone/iPad.

The aim of this scorecard element was to document the availability of country-specific risk assessment models (their uptake is considered separately in Chapter 4b). The score was based on the availability of risk assessment models and specific guidance for their use.

**Methods**

The availability of country-specific FRAX models was provided at the FRAX web site. The availability of other risk engines was determined from an IOF questionnaire to the EU Osteoporosis Consultation Panel undertaken in December 2012 together with a review of country-specific assessment guidelines. The metrics sought were the availability of country-specific risk models and whether national guidance was provided on how results from these assessments should be used in clinical practice.

**Results**

Risk assessment models were available in 21 of the member states (Table [33](#Tab33){ref-type="table"}). The majority were based on FRAX. In Germany, probability-based fracture risk assessment comprises a component of national guidelines, but is not FRAX-based \[1\]. Alternative assessment algorithms are also available in the Netherlands \[3\]. In the UK both FRAX and QFracture has been approved \[6\]. No models are available for Bulgaria, Cyprus, Estonia, Latvia, Luxembourg and Slovenia due to the lack of appropriate epidemiology of fracture on which these could be based. In countries where a model is available, a small majority (12/21) provide guidance on its application to clinical practice.Table 33Provision of risk assessment models in the EU and guidance on their application to clinical practiceFRAX model availableOther modelsGuidanceCommentsAustria✓--✓Belgium✓--✓Bulgaria------Cyprus^a^------Czech Republic✓--NoDenmark✓--NoEstonia------Finland✓--✓France✓--✓Germany✓Yes✓DVO model \[1\]Greece✓^b^--✓Hungary✓--✓Ireland✓^b^----^c^Italy✓----^c^Latvia------^c^Lithuania✓^b^--NoLuxemburg------^c^Malta✓--NoNetherlands✓Yes✓CBO \[3\]Poland✓--✓Portugal✓^b^--✓Romania✓----^c^Slovakia✓--No^a^Slovenia----NoSpain✓--NoSweden✓--✓UK^d^✓Yes✓QFracture \[2\]Europe----✓^a^Uses Greek FRAX tool as a surrogate model^b^Available from June 2012 and September 2012 (Portugal);^c^Noted in guidelines but without guidance; ^c^ to be implemented.^d^Guidance not provided by NICE

European guidance that can be applied to member states has been recently published for postmenopausal and glucocorticoid-induced osteoporosis \[7, 8\].

**Score allocation**

The score was based availability of country-specific risk models and whether national guidance was provided on how results from these assessments should be used in clinical practice as given in Table [34](#Tab34){ref-type="table"}.Table 34Criteria for allocating scores

The score assigned to each country is shown in Fig. [24](#Fig24){ref-type="fig"}.Fig. 24The score assigned to each country on the basis of its provision of fracture risk assessment algorithms. The star denotes that guidance given by the National Osteoporosis Guideline Group scores 3 but the score based on NICE is less

**Comment**

Risk assessment models for fractures based on FRAX were available in 21 out of 27 countries. In some countries (UK, Germany and the Netherlands) other models are also available. However, guidance on the use of risk assessment was available in only 12 out of 27 countries.
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**3e Quality of guidelines for assessment and treatment**

**Domain**

Service provision---scorecard element

**Background and aims**

The aim of guidelines is to provide an information platform for the assessment and treatment of osteoporosis so that appropriate treatment is directed to individuals at high fracture risk. Their scope most commonly includes postmenopausal osteoporosis, glucocorticoid-induced osteoporosis and osteoporosis in men. Less commonly, guidelines are available for the assessment of falls risk and its treatment. Ideally, guidelines should be based on systematic literature reviews and any recommendations supported by an adequate level of evidence.

The aim of this scorecard element was to determine the scope and quality of guidelines available in the EU27 countries.

**Methods**

Data were acquired by an IOF questionnaire to the EU Osteoporosis Consultation Panel undertaken in December 2012. Respondents were asked whether national guidelines were available for the assessment and/or treatment of osteoporosis. Responses were used to update an earlier audit of the IOF \[1, 2\]. Where guidelines were available, additional information was requested on their scope and quality.

Scope of guideline: Does it relate to postmenopausal women (PMW), men or glucocorticoid-induced osteoporosis (GIOP).

AGREE criteria: The quality of guidelines was judged according to the criteria developed the Appraisal of guidelines for research & evaluation (AGREE) next steps consortium \[3\] under 7 general domains (see footnote[1](#Fn1){ref-type="fn"}).

**Results**

Guidelines for the management of osteoporosis were available in the majority of member states (unavailable in Cyprus and Malta). All of the remaining counties had guidelines available for postmenopausal women (Table [35](#Tab35){ref-type="table"}). 17 of 25 countries had guidelines for osteoporosis in men and 19 had guidelines for glucocorticoid-induced osteoporosis. The availability of guidelines does not necessarily improve disease management and in some countries (e.g. Italy, Spain and UK) multiple guidelines were available from different sources that are likely to confuse rather than clarify clinical practice.Table 35Availability and scope of guidelines for the assessment and treatment of osteoporosis in the EU \[IOF audit\]Developed (year)Scope^a^AGREE criteriaScoreAustria2010PMW, men, GIOP58Belgium2005--11PMW, men, GIOP47Bulgaria2007PMW, men, GIOP69Cyprusna--00Czech Republic2003--10PMW, GIOP46Denmark2009PMW45Estonia2012PMW, men, GIOP58Finland2013PMW, men, GIOP710France2012PMW, men, GIOP56Germany2009PMW, men, GIOP710Greece2009--12PMW, men, GIOP58Hungary2003--11PMW, men, GIOP58Ireland2011PMW, men13Italy−2011PMW, men, GIOP710Latvia2011PMW, men, GIOP710Lithuania2011PMW77Luxemburg2010PMW77Maltana--00Netherlands2011--12PMW, men, GIOP710Poland2011--12PMW, men, GIOP36Portugal2011PMW78Romania2011PMW, men, GIOP69Slovakia2006--10PMW, GIOP79Slovenia2002PMW23Spain2004--11PMW, men, GIOP4.56.5Sweden2008PMW, men, GIOP710UK^b^2008PMW, men, GIOP710^a^ *PMW* postmenopausal women, *GIO* glucocorticoid-induced osteoporosis^b^Relates to guidance provided by the National Osteoporosis Guidelines Group \[4\]. National guidance with less scope also available from NICE \[5--7\]

**Score criteria**

A positive response in each AGREE category contributed a point to the score (maximum 7 points). Up to 3 additional points was given for the scope of the guideline (PMW, men, GIOP) to give a maximum score of 10. Where more than one guideline was available, a composite mean was used. Scores for each country were categorised as shown in Table [36](#Tab36){ref-type="table"}.Table 36Criteria for allocating scores

**Score allocation**

The score allocation and grade for each country is shown in Fig. [25](#Fig25){ref-type="fig"}.Fig. 25Score allocation based on the scope and quality of guidelines available for the assessment and treatment of osteoporosis. For the UK (star), the score for guidance provided by NICE is 8 and hat provided by the National Osteoporosis Guidelines Group has a score of 10 \[IOF audit\]

**Comment**

There was a large variation **i**n the extent and quality of national guidelines according to the AGREE criteria. It should be noted that a high score reflects the quality of the process, but not necessarily the quality of the content.
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**3f Guideline criteria for assessment and treatment**

**Domain**

Service provision---supplementary information

**Background and aims**

The aim of this section was to summarise the differences in the application of guidelines to clinical practice and, in particular, to identify where guideline recommendations conflicted with reimbursement policy.

**Methods**

A review was undertaken of guidelines covering the assessment and treatment of osteoporosis in each EU member state that was available in English or French. Additionally, data were acquired from a structured IOF questionnaire administered to the EU Osteoporosis Consultation Panel undertaken in December 2012. Information requested included whether guidelines addressed population-based screening, the tools used for assessment, and the tools to decide eligibility for treatment. An enquiry was also made whether risk assessment or treatment recommendations were compatible with reimbursement policy.

**Results**

Guidelines were not available in Cyprus or Malta. In the remaining countries, guidelines were generally less than 5 years old, often related to updating, with one exception (Slovenia, 2002).

Population screening was considered in guidelines from 15 of 25 countries. Although reviewed, population based screening was not recommended. In Hungary, however BMD is offered free of charge to women aged 50 years or more, though the uptake is low.

Guidelines in 24 of the 25 countries covered the assessment of fracture risk (the exception was the Czech Republic). The most common tools used for fracture risk assessment were age in 22/25 countries (exceptions were Lithuania, Slovakia and Sweden) and bone mineral density (in all countries). The use of fracture risk assessment algorithms was less consistent and noted in 17 countries (Fig. [26](#Fig26){ref-type="fig"}). FRAX was the most widely used instrument though in Germany the DVO tool was recommended \[1\]. In the UK, both FRAX and QFracture has been approved \[2\].Fig. 26The distribution of the use of risk assessment models in assessment guidelines of the EU27 countries \[IOF audit\]

Guidelines in all 25 countries covered eligibility for treatment with a general commonality of approach. Eligibility for treatment depended on prior fracture (except Denmark and Sweden), age (except Lithuania, Slovakia and Sweden) and BMD (all countries). As was the case for assessment (see Chapter 3d), risk assessment tools provided criteria for intervention in fewer (17/25) countries (Fig. [26](#Fig26){ref-type="fig"}). In Italy, Spain and the UK, there are several guidelines from different sources that give different recommendations.

Several counties reported incompatibilities between recommendations for risk assessment or treatment with reimbursement policy (Table [37](#Tab37){ref-type="table"}). For example, guidelines recommended the use of FRAX which was not provided for in reimbursement provision (Belgium, Poland, Romania and Slovakia), specific treatments were recommended but not reimbursed (Poland, Romania) and central DXA was recommended for risk assessment but other techniques (peripheral BMD and QCT) were reimbursed (Lithuania). In Luxembourg, the BMD thresholds for treatment differ from the criteria for reimbursement for DXA. In other instances, guidelines recommended the use of risk factors such as a prior fragility fractures but reimbursement was solely dependent on BMD (Lithuania, Romania). With regard to treatment, reimbursement was limited in time (18 months) but treatment recommended on a long-term basis (Lithuania). A problem inconsistently related to reimbursement was that multiple guidelines gave conflicting recommendations (Italy, Spain, and the UK). Another barrier to treatment is that reimbursement was only granted where the prescription was issued by a specialist (e.g. Czech Republic).Table 37Scope of guidelines for patient assessment, treatment and consistency with reimbursement policy \[IOF audit\]DateAssessmentCompatible/consistentTreatmentCompatible/consistentAustria2010YesYesYesYesBelgium2005--11YesNoYesNoBulgaria2007YesNoYesNoCyprusna--------Czech Republic2003--10NoNoYesNoDenmark2009YesYesYesEstonia2012YesYesYesYesFinland2013YesYesYesYesFrance2012YesYesYesYesGermany2009YesNoYesNoGreece2009YesYesYesYesHungary2011YesYesYesYesIreland2011YesNoYesYesItaly−2011YesYes/noYesNoLatvia2011YesYesYesYesLithuania2011YesNoYesNoLuxembourg2010YesNoYesYesMaltana--------Netherlands2011--12YesYesYesYesPoland2011--12YesNoYesNoPortugal2011YesYesYesYesRomania2011YesNoYesNoSlovakia2006/09/10YesNoYesYesSlovenia2002YesYesYesYesSpain2004--11Yes/noYes/noYes/noYesSweden2012YesYesYesYesUK2008--12YesYes/noYesYes*na* not applicable, *nr* not recorded

**Score allocation**

Supplementary information, no score allocation

**Comment**

Risk assessment or treatment recommendations were compatible with reimbursement policy in approximately half of the EU member states.
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**3g Fracture liaison services**

**Domain**

Service provision---scorecard element

**Background and aims**

Fracture liaison services (FLS), also known as osteoporosis co-ordinator programmes and care manager programs, provide a system for the routine assessment and management of postmenopausal women and older men who have sustained a low trauma fracture \[1--4\]. Assessment includes DXA measurements, fall risk evaluation, and underlying secondary causes of osteoporosis. Although the importance of an incident fracture as a risk factor for further fracture is well recognised, the majority of patients presenting with a low trauma fracture do not receive appropriate assessment and treatment in the setting of standard hospital care. FLS address this need through a systematic approach to identifying such individuals and assessing their risk of further fractures and the need for treatment. Most FLS are based in secondary care although models in primary care have also been described. The clinical and cost-effectiveness of FLS has been demonstrated in several centres \[5--7\].

The aim of this scorecard element was to document the proportion of hospitals that have a fracture liaison service in the EU27 countries.

**Methods**

Information was acquired from a structured IOF questionnaire administered to the EU Osteoporosis Consultation Panel undertaken in December 2012. Correspondents were asked to estimate the proportion of hospitals in each member state that have a scheme in place that refers fracture patients over 50 years old to a fracture liaison service. Scoring was based on the distribution of the estimates.

**Results**

No estimates were provided from Malta. Of the remaining countries, no fracture liaison services were reported from Greece, Latvia, Portugal, Romania and Slovakia. The presence of FLS was acknowledged in the remaining member states, but for most countries, the proportion of hospitals that have a scheme in place was less than 10 %. Higher rates were reported from Austria, Cyprus, Czech Republic, Estonia, Finland, Hungary, Netherlands and Sweden (Fig. [27](#Fig27){ref-type="fig"}).Fig. 27The proportion of hospitals (%) with FLS in the EU countries \[IOF audit\]

**Score criteria**

The proportion of hospitals in each member state that had fracture liaison services (FLS) in place were categorised as shown in Table [38](#Tab38){ref-type="table"}.Table 38Criteria for allocating scores

**Score allocation**

Figure [28](#Fig28){ref-type="fig"} shows the scores allocated by countryFig. 28Scores allocated by country on the availability of fracture liaison services in hospitals by member state \[IOF audit\]

**Comment**

The information provided needs to be interpreted cautiously. It provides a perception of how many hospitals of a country has a fracture nurse working in a fracture liaison service, but is an expert opinion and not based on numerical evidence. Moreover, no account was taken of FLS in primary care. In addition, no information was available on the performance of the FLS. It is also notable that a colour code of green should not be interpreted as an endorsement since provision should, in the view of the panel, be expected in the majority of hospitals or care centres.

**References**

1\. Cooper C, Mitchell P, Kanis JA (2011) Breaking the fragility fracture cycle. Osteoporos Int 22:2049--50.

2\. Eisman JA, Bogoch ER, Dell R et al. (2012) Making the first fracture the last fracture: ASBMR task force report on secondary fracture prevention. J Bone Miner Res 27: 2039--46

3\. International Osteoporosis Foundation (2012) Capture the fracture: a global campaign to break the fragility fracture cycle. IOF, Nyon. Accessible at [www.iofbonehealth.org](http://www.iofbonehealth.org)

4\. Sale JE, Beaton D, Posen J, Elliot-Gibson V, Bogoch E (2011) Systematic review on interventions to improve osteoporosis investigation and treatment in fragility fracture patients. Osteoporos Int 22: 2067--82.

5\. Dell R (2011) Fracture prevention in Kaiser Permanente Southern California. Osteoporos Int 22 (Suppl 3): 457--60

6\. Marsh D, Akesson K, Beaton DE, Bogoch ER, Boonen S, Brandi ML, McLellan AR, Mitchell PJ, Sale JE, Wahl DA; IOF CSA Fracture Working Group (2011) Fracture liaison services for the evaluation and management of patients with osteoporotic fracture: a cost-effectiveness evaluation based on data collected over 8 years of service provision. Osteoporos Int 22: 2051--65

7\. McLellan AR, Wolowacz SE, Zimovetz EA, Beard SM, Lock S, McCrink L, Adekunle F, Roberts D (2011) Fracture liaison services for the evaluation and management of patients with osteoporotic fracture: a cost-effectiveness evaluation based on data collected over 8 years of service provision. Osteoporos Int. 2011 22: 2083--98.

**3h Use of quality indicators**

**Domain**

Service provision---scorecard element

**Background and aims**

The use of indicators to systematically measure the quality of care provided to people with osteoporosis or associated fractures is a relatively new discipline, with the United States perhaps having the most developed system in place \[1\], as shown for use of healthcare quality indicators more broadly \[2\]. In the UK, the Department of Health Best Practice Tariff for hip fracture care has used financial incentives since April 2010 to drive adherence with the six core benchmarks, which include an assessment of bone health and risk of falling. In the 2 years following introduction of the tariff, the proportion of patients with fragility hip fracture for whom all six standards were met rose from 24 to 55 % \[3\].

The aim of this scorecard element was to document the systematic approaches to enhance the quality of osteoporosis care or secondary prevention of fragility fractures in the EU.

**Methods**

Data were acquired by an IOF questionnaire to the EU Osteoporosis Consultation Panel undertaken in December 2012. Respondents were asked whether national systems were in place that systematically collect data on the quality of care provided to people with osteoporosis or the secondary prevention of fragility fractures. Further questions were whether the systems use measures (quality indicators or standards) that are documented on a regular basis (e.g. annually) and use a set of explicit criteria to assess performance.

**Results**

Few countries had systems that include quality measures *plus* a regular audit for national health care agencies (Denmark, Germany, and UK). In the United Kingdom, osteoporosis/ secondary prevention of fragility fractures has been included in the Quality and Outcomes Framework as part of the general practitioner contract from April 2012 \[4\]. The Quality and Outcomes Framework is a pay for performance scheme for general practice in the UK, which awards 'achievement points' for adhering to procedural and treatment guidelines and meeting intermediate outcome targets for over 130 quality indicators. In the UK, there is also a system of clinical audits in place, seeking to improve patient care and outcomes through systematic review of care according to explicit criteria and the implementation of change. These include the National Audit of Falls and Bone Health in Older People \[5\] and the continuous National Hip Fracture Database \[3\]. In Germany, selected providers and health insurance funds have, in the framework of 'integrated care contracts' entered into agreements on coordinated osteoporosis care which may include the documentation of care standards to enable tracking of the quality of care provided. The nature and contents of these contracts vary across regions \[6\]. There is a systematic and nationwide collection of quality indicators for the inpatient care following hip fracture \[7\]; however a systematic collection of indicators that would permit assessment of care quality of those with osteoporosis and in the secondary prevention of fragility fractures is not in place.

Several other counties (Bulgaria, Finland, Greece) have systems that provide quality indicators or standards that are documented on a regular basis (Table [39](#Tab39){ref-type="table"}) but it is unclear whether criteria are developed to assess performance. In Slovakia, quality measures are in place but no provision is made for regular audit.Table 39Systems that provide quality indicators in the context of osteoporosis and fractures in the European Union \[IOF audit\]Systems in placeTargetsScoreAustriaNo1BelgiumNo1BulgariaYesHip fractures2CyprusNo1Czech RepublicNo1DenmarkYesHip fractures3EstoniaNo1FinlandYesHip fractures2FranceNo1GermanyYesHip fractures3GreeceYesHip fractures2HungaryYesFragility fractures2IrelandNo1ItalyNo1LatviaNo1LithuaniaNo1LuxemburgNo1MaltaNo1NetherlandsYes3PolandNo1PortugalNo1RomaniaNo1SlovakiaYesOsteoporosis, fragility fracture, falls2SloveniaNo1SpainNo1SwedenYesFractures, treatment2UKYesHip fracture, falls, fragility fractures3

**Score criteria**

The score was based on the presence of systems and their use as quality indicators as given in Table [40](#Tab40){ref-type="table"}Table 40Criteria for allocating scores

**Score allocation**

Score allocation for quality indicators by country are given in Fig. [29](#Fig29){ref-type="fig"}.Fig. 29Score allocation for quality indicators by country \[IOF audit\]

Given the relative novelty of using QI for the tracking of quality of care provided to people with osteoporosis or associated fractures in the European region, it should be recognised that the score is a 'proxy' measure. Though audited quality measures have been introduced in some countries, the UK is far advanced in this regard.
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**Chapter 4. Service uptake**

**4a Uptake of DXA**

**Domain**

Service uptake---background information

**Background and aims**

The ability to assess osteoporosis depends in part on the availability of bone mass measurements at the lumbar spine and hip with dual energy X-ray absorptiometry (DXA). The requirement for the technology will depend on the assessment guidelines in each member state and the policy with respect to the use of DXA to diagnose osteoporosis and monitor treatment. The uptake of this technology depends upon the efficiency with which the technology is used, the ease of patient access (e.g. travelling time), regulatory constraints and barriers to reimbursement.

The aim of this element was to compare the access to DXA measured as a function of the requirements recommended in relevant assessment guidelines.

**Methods**

Ideally, uptake should be measured as the number of scans undertaken in relation to treatment guidelines in each member state. Such data are not available in the EU as a whole. Data are available by age and sex from the National Health Service of Denmark and are reported here \[Abrahamsen, 2011\].

**Results**

The Danish National Health Service release claims data for DXA and was available most recently for 2005. The uptake of BMD testing by age and sex for 2005 is shown in Fig. [30](#Fig30){ref-type="fig"}. Although the accuracy of the claims to tests is uncertain and tests in the private sector are not captured, the uptake was very low even accounting for these errors. Thus, guidelines based on BMD testing indicate that 173 women/1,000 women aged 50 years or more qualify for BMD testing \[2\] whereas the corresponding figure for Denmark was 28.6 or 16 % of the desired uptake. The use of probability-based guidelines reduces the number of scans needed to 81/1000 women \[2\] but is still considerably higher than that attained in Denmark. The uptake in men over the age of 50 years was 4 times lower (7/1000) than in women. In men and women combined the uptake of DXA was 18.5/1000.Fig. 30The uptake of BMD testing in men and women by age and sex in Denmark in 2005 \[Data kindly provided by Bo Abrahamsen, Gentofte Hospital Copenhagen, Denmark\]

**Score allocation**

No score allocation

**Comment**

More information is required from all member states on the utilisation of DXA with regard to guidelines on the assessment and monitoring of treatment. The available evidence from Denmark, a country moderately provided with DXA machines, is that service uptake is less than optimal.

**References**
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**4b Uptake of risk assessment algorithms**

**Domain**

Service uptake---scorecard element

**Background and aims**

FRAX is an algorithm that determines fracture probability in individuals by integrating the weight of important clinical risk factors for fracture and mortality risk, with or without information on BMD (see Chapter 1 g). Each tool is country-specific and calibrated to the national epidemiology of fracture. They were developed by the WHO Collaborating Centre for Metabolic Bone Diseases at Sheffield, UK and launched in 2008 \[1, 2\]. The FRAX tools ([www.shef.ac.uk/FRAX](http://www.shef.ac.uk/FRAX)) compute the 10-year probability of hip fracture or a major osteoporotic fracture. A major osteoporotic fracture is a clinical spine, hip, forearm and humerus fracture. The use of the tool improves risk assessment compared to the use of BMD alone.

FRAX is now a component of many national guidelines for the assessment of osteoporosis (see Chapter 3f) and European guidelines for postmenopausal osteoporosis and glucocorticoid-induced osteoporosis \[3, 4\]. The aim of this element was to determine the usage of FRAX in the EU27 countries.

**Methods**

Each FRAX model on the web counts the number of calculations performed for that particular country. A problem with these data is that some countries, particularly those without a country-specific FRAX model, may use a surrogate. For example, the UK model was adopted as a surrogate in Poland before the advent of a Polish model and the Greek model is presently used in Cyprus. For this reason, we assessed the number of calculations by the source of the calculation \[Google Analytics\]. FRAX usage was computed as the number of calculations originating from each country and expressed as calculations/million of the general population over a period of one year (November 2010 to December 2011).

**Results**

The web-based usage of the models is shown in Table [41](#Tab41){ref-type="table"} which shows considerable heterogeneity in uptake. Belgium, UK, Luxembourg, Sweden and Ireland have the highest usage of FRAX. Lithuania, Latvia, Germany and Bulgaria have the lowest uptake. The average uptake for the EU27 was 880 calculations/million of the general population.Table 41Uptake of FRAX in EU counties expressed as the number of calculations per million of the general populationCountryCalculations /millionCountryCalculations /millionCountryCalculations /millionAustria1534Germany83.5Netherlands526Belgium5003Greece502Poland338Bulgaria112Hungary1205Portugal1039Cyprus272Ireland1643Romania230Czech Republic175Italy518Slovakia372Denmark942Latvia57.7Slovenia1322Estonia207Lithuania28.5Spain1115Finland444Luxembourg2293Sweden1911France314Malta1541UK2293

Country-specific models are available in 21 member states (see Chapter 3d). FRAX models are not available for Bulgaria, Cyprus, Estonia, Latvia, Luxembourg and Slovenia. There is, however, no clear relationship between the availability of a country-specific model and the use of FRAX.

**Score criteria**

FRAX calculations/million of the general population/year was categorised by tertiles as given in Table [42](#Tab42){ref-type="table"}Table 42Criteria for allocating scores

**Score allocation**

Countries, ranked and categorised by score, are shown in Fig. [31](#Fig31){ref-type="fig"}.Fig. 31The uptake of fracture risk assessment tools as judged by the use of FRAX from each EU country by score category. \*See comment below with regard to Germany

**Comment**

These data underestimate the use of FRAX by approximately 25 % due to the availability of FRAX on bone densitometers. FRAX calculations on densitometers are not performed through the web site. In addition, hand held calculators are used in several countries, particularly in Poland. FRAX is also available as an application on the iPhone.

These data underestimate the use of risk assessment in Germany. Fracture risk assessment comprises a component of the German national guidelines, but is not FRAX based. Alternative assessment algorithms are also available in the UK and the Netherlands.

The caveats above indicate that the figures are conservative. Even so, there are reasons to believe that FRAX is underutilised. For example, the use of FRAX in Denmark (942 calculations/million per year) is much lower than the number of BMD tests/year (18,500 /million per year; see Chapter 4a). Thus, a colour code of green should not be interpreted as an endorsement of appropriate uptake.
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**4c Treatment uptake and treatment gap**

**Domain**

Service uptake---scorecard element

**Background and aims**

Many surveys indicate that a minority of men and women at high fracture risk receive treatment \[1, 2\]. The aim of this section was to estimate the proportion of women at high risk that receives therapy for osteoporosis in the EU27.

**Methods**

The proportion of patients eligible for treatment depends on defining an intervention threshold, i.e. the risk of fracture above which treatment can be recommended. Though treatment guidelines are available in nearly all EU member states \[3\] (see Chapters 3e and 3f), there is no uniform approach to intervention thresholds across the EU27.

The advent of FRAX ([www.shef.ac.uk/FRAX](http://www.shef.ac.uk/FRAX)) in 2008 provided a clinical tool for the calculation of fracture probability that has been applied to the development of intervention thresholds \[4\]. For the purposes of this analysis, the intervention threshold set was at the 10-year fracture probability equivalent to women with a prior fragility fracture without knowledge of BMD as adopted in several European guidelines \[5--7\]. Thus, the intervention threshold can be likened to a 'fracture threshold' expressed in terms of fracture probability. The proportion of women who exceed the fracture threshold was computed by simulation \[8\] based on the distribution of the risk-score among the cohorts used by WHO to develop FRAX and the epidemiology of fracture and death in each EU country.

The number of patients treated in each country was computed from IMS Health sales data for 2010 and expressed as treatment years \[3\]. The use of hormone replacement treatment was excluded since the majority of women take hormone replacement treatment for menopausal symptoms rather than for osteoporosis. An adjustment factor (estimated from data from the Swedish Prescribed Drug Register) was used to correct for suboptimal adherence. The number of women potentially treated was subtracted from the number of women exceeding the intervention threshold and expressed as a percentage. No sales data were available for Cyprus or Malta and these two countries were therefore excluded from analyses.

**Results**

Table [43](#Tab43){ref-type="table"} indicates that there is wide inter-country variation in the treatment penetration of women at high risk for osteoporotic fractures. The treatment gap varied from 25 % in Spain to 95 % in Bulgaria. Large treatment gaps were identified in countries with populations at both high and low risk of fracture. In total in the EU, it is estimated that, out of the 18.4 million women that exceed the risk level, 10.6 million are untreated. These figures are conservative since an undetermined proportion of low-risk women will have received treatment (see comments, below).Table 43Number of women eligible for treatment, treated and treatment gap in 2010 \[3\]CountryNumber potentially treated (000s)Number exceeding fracture risk threshold (000s)Difference (000s)Treatment gap (%)Austria13928214351Belgium21440218847Bulgaria1324022795Czech Republic7933025176Denmark8719010354Estonia7484186Finland5317211969France1,3902,4371,04743Germany7303,2312,50177Greece33348214931Hungary2383329428Ireland911243326Italy1,0692,6351,56659Latvia12806885Lithuania111099890Luxembourg916743Netherlands24260536360Poland2451,12788278Portugal26942515637Romania10059949983Slovakia751487349Slovenia35622744Spain1,2771,70943225Sweden10035825872UK1,0642,2981,23454EU277,88118,44110,56057

**Score criteria**

Countries were categorised by approximate tertiles as shown in Table [44](#Tab44){ref-type="table"}.Table 44Criteria for allocating scores

**Score allocation**

The score allocation and the treatment gap for each country is shown in Fig. [32](#Fig32){ref-type="fig"}.Fig. 32Proportion of women of women at high risk that are untreated (treatment gap) in 2010 ranked by country and score \[3\]

**Comment**

It is unlikely that 100 % of sales are captured in any country but it is difficult to define the magnitude of underestimation. IMS Health attempts to correct for under- and over-estimation, and in the absence of any additional information, there is no further adjustment of the available sales figures.

Another difficulty in interpretation may arise from parallel trade. IMS Health adjusts the data for parallel trade in some countries. The countries for which adjustments have been made are Austria, Belgium, Czech Republic, Denmark, Finland, France, Germany, Italy, the Netherlands, Poland, Spain, Sweden and the UK.

The pattern of use within countries cannot be ascertained in this analysis, so that it is not possible to determine whether treatment is targeted appropriately to high risk individuals. There are several indicators that suggest that the targeting of treatment is heterogeneous in the EU27. Good evidence comes from the Global Longitudinal Study of Osteoporosis in Women (GLOW) which is a general practice based observational cohort study in women aged 55 years or more conducted in 10 countries, including several EU countries \[1\]. In the EU countries, there was heterogeneity of treatment uptake between countries with the lowest proportion of women aged 55 years or more treated in the Netherlands (7 %) and the highest in Spain (23 %) (Fig. [33](#Fig33){ref-type="fig"}). Although treatment uptake was higher in women at very high risk (a prior hip or spine fracture), a minority (45 %) were receiving treatment in these countries. Again, there was heterogeneity in treatment uptake that ranged from 36 % in the Netherlands to 57 % in Italy. Moreover, some low-risk women were targeted in all countries.Fig. 33Proportion of women receiving treatment in six EU member states according to category of risk. All women refer to women aged 55 years or more (*n* = 24,249). Low risk comprises women aged less than 75 years with a *T* score for BMD in the range of osteopenia, no prior fracture, no maternal hip fracture or osteoporosis (*n* = 1166). High risk refers to women reported to have a BMD measurement in the range of osteoporosis (*n* = 5258). Very high risk comprises women with a previous hip or spine fracture (*n* = 913) \[9\]

These data demonstrate that a large number of women at high risk of fractures are not receiving treatment, that a substantial number of women at low risk are prescribed treatment (13--22 %) and confirm important differences in the uptake of treatment between countries. Thus, a colour code of green should not be interpreted as an optimum.
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**4d National prescription database**

**Domain**

Service uptake---Background information

**Background and aims**

IMS Health provides sales data that can be examined by country but give no information on who receives the agent in question or the purpose for which it was given (see Chapter 4c). Such data are not available on an EU-wide basis. However, several EU countries have a National Prescription Database that can provide more detailed information.

**Methods**

The National Prescription Databases of Sweden was accessed to determine the number of individuals by age who had received a prescription for a bone-active medication in 2010. Exposure to oestrogens was not included. Treatment days (daily defined doses; DDD) were computed from the prescription refills in 2010 and converted to person-years of exposure to treatment (DYD). Treatment rates were expressed as a proportion of the Swedish population \[1\].

**Results**

The numbers of individuals by age who had received bone-active medication and the DYDs are shown in Table [45](#Tab45){ref-type="table"}. Treatment uptake is expressed as the number of individuals who were taking a bone-active medication (i.e. filled a prescription) and the number of person-years of treatment in that year. For example, there were 18,931 men and women aged 80--84 years who had been prescribed a treatment in 2010. The total prescription base for that age range was equivalent to 13,888 person-years. Over all ages, 3 % of the Swedish population aged 50 years or more received treatment.Table 45Population size, patients treated and patient-years of treatment by age in Sweden 2010Age (years)Population (000)Patients treatedPatient-years of treatmentDYD50--545772,3471,7791,77955--595735,3283,9533,95360--6462610,3467,6657,66565--6953515,68511,69311,69370--7437817,08112,65912,65975--7930318,80214,05514,05580--8424718,93113,88813,88885+24916,88312,39412,39450+3,488105,40378,086

Figure [34](#Fig34){ref-type="fig"} shows the uptake of bone-active agents (oestrogens excluded) for 2010. For example, there were 77 prescriptions filled per 1,000 of the population aged 80--85 years in 2010. The number of unique patients that received a prescription for that age range was 56 per 1,000 person-years. These figures are low when compared with the population at high risk. For example, the number of patients in this age range that received a treatment was approximately 13,500 representing 5.6 % of the population at this age. In contrast, the number of individuals in this age range with osteoporosis is estimated at 67,800 and those with a fracture probability above a fracture threshold is estimated at 32,000 \[2\]. Thus, although treatments are targeted by age, the majority of high risk individuals remain untreated.Fig. 34The number (rate/thousand) of prescriptions for bone-active medications and the number of patients filling a prescription for bone-active medications in 2010 \[National Prescription Databases of Sweden\]

**Score allocation**

None---supplementary information

**Comment**

Note that the data do not give information on persistence or compliance. Although treatments are targeted by age, the majority of high risk individuals remain untreated.
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**4e Treatment gap and treatment need**

**Domain**

Service uptake---Background information

**Background and aims**

Patients who sustain a prior fragility fracture are at great risk of a future fracture. The risk is increased approximately two-fold \[1\] and is largely independent of BMD \[2\]. The risk is sufficiently high that many treatment guidelines in the EU recommend that postmenopausal women with a prior fragility fracture should be offered treatment. However, the majority of such patients are untreated so that the prevalence of a prior fracture in the community provides an index of opportunity lost. This may be set against the treatment gap to provide an index of the relationship between service provision and service need. The aim of this element was to provide an index of the prevalence of a prior fracture in the EU member countries in relation to the treatment gap.

**Methods**

For the purposes of this report, a prior fracture was defined as a hip or clinical vertebral fracture in an individual who was alive in 2010 that had occurred after the age of 50 years before 2010. The unit was the individual so that multiple fractures at the same site in one individual were only counted as one prior fracture of that site. A micro-simulation model, programmed in TreeAge, was used to simulate the prevalence of prior hip and vertebral fractures from incidence data \[3\]. Note that the prevalence of a hip or clinical vertebral fracture will underestimate the prevalence of previous fragility fracture at other sites.

More complete information on prior fractures is available for six member states (France, Germany, Italy, Spain, Sweden and the UK) using a different approach \[4\] and is also considered.

For the treatment gap, the data from Chapter 4c were used \[1\].

**Results**

In 2010, approximately 6.7 million men and women in the EU had sustained a prior hip or clinical spine fracture before 2010 (Table [46](#Tab46){ref-type="table"}). As would be expected, the prevalence increased progressively with age. At the age of 95 years or more, the prevalence of a prior hip fracture was 22.5 % and for a prior vertebral fracture was 14.5 % \[1\]. Overall, 1.8 % of the population at the age of 50 years or more had a prior hip fracture and 1.9 % a prior clinical spine fracture.Table 46Estimated number and percentage of men and women aged above 50 years with a prior hip or vertebral fracture by country in 2010 \[3\]Hip fractureVertebral fracture*A* + *B*Number% Population (*A*)Number% Population (*B*)Austria74,2702.483,6232.75.1Belgium74,4851.980,7062.03.9Bulgaria31,3701.132,7801.12.2Cyprus4,9211.66,1502.03.6Czech58,9791.664,3401.73.3Denmark49,7462.558,5732.95.4Estonia7,3501.57,4861.53.0Finland34,1811.637,1921.83.4France434,6741.9435,5071.93.8Germany669,7992.0775,5292.34.3Greece87,4132.1101,7602.44.5Hungary57,2251.660,5941.63.2Ireland17,2471.418,7421.52.9Italy517,1262.2539,0362.34.5Latvia11,8621.511,5751.42.9Lithuania13,0461.212,7821.12.3Luxemburg2,4461.52,7901.83.3Malta1,9741.32,3161.52.8Netherlands74,5941.382,2061.42.7Poland139,2121.0144,8631.12.1Portugal52,1061.353,6531.42.7Romania72,0241.082,8291.12.1Slovakia28,0651.632,4881.93.5Slovenia12,4291.614,3061.93.5Spain210,5601.3212,4281.32.6Sweden98,9522.8111,3483.26.0UK418,8811.9437,4992.03.9EU273,254,9391.83,503,1011.93.7

The ranked prevalences by country are shown in Fig. [35](#Fig35){ref-type="fig"}. As would be expected, there was a close relationship between fracture risk (see Chapter 1b) and the proportion of the population with a prior hip or clinical vertebral fracture.Fig. 35The proportion (%) of the population aged 50 years or more with a prior hip or vertebral fracture in 2010 \[3\]

Table [47](#Tab47){ref-type="table"} summarises data for the EU5+Sweden which shows the prevalence of *all prior fractures* in 2010 in comparator studies. The estimation of prior vertebral + prior hip fracture, shown in Fig. 35, appears to capture approximately 30 % of prior fractures. This suggests that the prevalence of a prior clinical spine or hip fracture is a reasonable surrogate for the service needs of each member state.Table 47The prevalence (%) of a prior fracture at sites associated with osteoporosis in men and women aged 50 years or more compared with the prevalence of a prior vertebral or hip fracture as given in Table 46. The last column shows the proportion (%) of prior fractures accounted for by hip or clinical vertebral fracture \[3\]CountryAuthorPrevalence (%)EU/CComparatorEU27FranceCawston 2012 \[5\]11.23.834GermanyGauthier 2012 \[6\]14.14.330ItalyPiscitelli 2012 \[7\]16.24.528SpainGauthier 2012 \[8\]8.92.629SwedenGauthier 2011 \[4\]22.66.027UKGauthier 2011\[9\]10.33.939Average30

The relationship between this service need and the treatment gap is shown in Fig. [36](#Fig36){ref-type="fig"} for each of the EU member states and for the EU countries combined. The top right quadrant can be considered to represent countries of high need but poor provision. These included Denmark and Sweden. The other extreme (lower left quadrant) represents countries of lower need but better provision. These included Estonia, Ireland Hungary and Spain.Fig. 36The relationship between the prevalence of a prior spine or hip fracture (service need) and the treatment gap (service provision) in the EU27 countries. The *horizontal* and *vertical lines* intersect at the EU average (weighted for population size) \[3\]. Country codes (ISO 3166--1 alpha-2); *AT* Austria; *BE* Belgium; *BG* Bulgaria; *CY* Cyprus; *CZ* Czech Republic; *DE* Germany; *DK* Denmark; *EE* Estonia; *ES* Spain; *FI* Finland; *FR* France; *GB* United Kingdom; *GR* Greece; *HU* Hungary; *IE* Ireland; *IT* Italy; *LT* Lithuania; *LU* Luxembourg; *LV* Latvia; *MT* Malta; *NL* Netherlands; *PL* Poland; *PT* Portugal; *RO* Romania; *SE* Sweden; *SI* Slovenia; *SK* Slovakia

**Score allocation**

Supplementary information, no score allocation

**Comment**

There is a wide variation in both (hip and spine) fractures and treatment gap between countries. This is of particular concern in countries with a high fracture burden and a high treatment gap.
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**4f Waiting time for hip surgery**

**Domain**

Service uptake---scorecard element

**Background and aims**

About 5 % of people with a hip fracture die within 1 month and about one quarter within 12 months. Most deaths are due to associated conditions and not to the fracture itself \[1\], reflecting the high prevalence of co-morbidity. In the EU27, hip fractures were estimated to result in approximately 11,000 premature deaths in women that were directly attributable to the fracture event in 2010. The corresponding numbers for men were estimated at approximately 9,000 \[2\]. A determinant of peri-operative morbidity and mortality is the time a patient takes to get to surgery which, in turn, is an early marker of a patient's progress following a hip fracture. Early surgery (\<48 h) is associated with a statistically and clinically significant reduction in mortality at 1 year and an increase in the proportion of patients returning to their original residence \[3\].

The aim of this scorecard element was to determine average waiting times for hip surgery in the EU member states.

**Methods**

Data were acquired by an IOF questionnaire to the EU Osteoporosis Consultation Panel undertaken in December 2012. Respondents were asked to provide information on the average waiting time for hip surgery after hip fracture. Countries were categorised according to average waiting times between hospital admission and surgical intervention. An additional indicator of management that was sought was the proportion of hip fracture cases that were managed surgically.

**Results**

Waiting times between admission to hospital and surgical intervention were on average 1 day or less in 7 countries, 1--2 days in 13 countries and greater than 2 days in 6 countries (Table [48](#Tab48){ref-type="table"}). Information was not recorded for Malta. More than 90 % of hip fracture cases received surgery in the majority of countries. Exceptions included Bulgaria, Czech Republic, Hungary and Italy where 75--90 % of cases received a surgical intervention.Table 48Average waiting times between hospital admission and surgical intervention and the proportion of hip fracture cases managed surgically \[IOF audit\]Waiting time (days)Surgical management (%)ScoreAustria1--2\>902Belgium\<1\>903Bulgaria1--275--902Cyprus2--3\>901Czech Republic1--275--902Denmark1--2\>902Estonia\<1\>903Finland1--2\>902France1--2\>902Germany\<1\>903Greece2--3\>901Hungary\<175--903Ireland2--3\>901Italy2--375--901Latvia\<1\>903Lithuania\<1\>903Luxembourg1--2\>902MaltanrnrNetherlands1--2\>902Poland1--2\>902Portugal2--3\>901Romania1--2\>902Slovakia1--2\>902Slovenia1--2\>902Spain2--3\>901Sweden\<1\>903UK1--2\>902*nr*, not recorded

**Score criteria and allocation**

Uptake was categorised by average waiting time for hip surgery (Table [49](#Tab49){ref-type="table"})Table 49Criteria for allocating scores

**Score allocation**

Score results are given in Table [48](#Tab48){ref-type="table"} and colour coded in Fig. [37](#Fig37){ref-type="fig"}.Fig. 37Countries categorised by the average waiting time for surgical intervention for hip fracture \[IOF audit\]

**Comment**

Note that average waiting times give no index of the dispersion around the mean
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**The scorecard**

SCOPE. The Scorecard for Osteoporosis in Europe, is an innovative tool that allows health and policy professionals to assess key indicators on the healthcare provision for osteoporosis in countries and between counties within the EU.

Scorecard key

AGREE criteria

Systematic search. How thorough was the evidence base? Were the guidelines based on a systematic literature review conducted at the time of the guideline development (or on a previously conducted review that was updated).

Recommendations: Were recommendations graded (e.g. A, B, C) according to the levels of evidence provided by the systematic review?

Stakeholder involvement: Was there involvement from patient organisations, primary care physicians, national/EU societies in the consultation process for the guidelines?

External review: Were the guidelines reviewed by independent experts? i.e. have they undergone a rigorous external review in addition to consultation.

Procedure for update: Were the guidelines updated as and when necessary or was there explicit mention of a provision to update the guidelines in the future?

Economic analysis: Were the recommendations underpinned by an economic analysis?

Editorial independence: Did the guidelines explicitly state that there was editorial independence of the writing group from any funding body?

The panel has received speaker fees, advisory board fees and/or unrestricted research grants from governmental and non-governmental sources. A full list of disclosures is available from the International Osteoporosis Foundation upon request.
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BMD

:   Bone mineral density, usually measured as the amount of calcium in bone per unit area.

BMI

:   Body mass index, an index of leanness or obesity measured from height and weight

CI

:   Confidence interval

CRF

:   Clinical risk factor, in this context for fracture

DALY

:   Disability-adjusted life year, a product of years of life lost and the remaining years of life disabled (i.e., disutility).

DDD

:   Defined daily dosage

Direct costs

:   Used in health technology assessment to describe direct healthcare costs (e.g., hospital admissions, medical examinations, drug therapy, etc.), the indirect costs (e.g., losses in productivity resulting from absence to work) and intangible costs (e.g. pain and suffering, poor quality of life).

DXA

:   Dual-energy X-ray absorptiometry, a method for measuring BMD

EFPIA

:   European Federation of Pharmaceutical Industries Association

EU27

:   The 27 member states of the European Union

FRAX

:   Fracture risk assessment tool developed by the WHO Collaborating Centre, University of Sheffield Medical School, UK. FRAX calculates the 10-year probability of a major osteoporotic fracture and hip fracture in individuals from clinical risk factors and BMD

GDP

:   Gross domestic product, the total value of goods produced and services provided in a country in 1 year

GLOW

:   Global Longitudinal Study of Osteoporosis in Women

ICD

:   International classification of diseases

IMS

:   Intercontinental Marketing Services

Incidence

:   The frequency of an event, usually expressed as a rate e.g. 10 per 1000 of the population/year.

IOF

:   International Osteoporosis Foundation

mg

:   Milligram

MPR

:   Medication possession ratio

NHANES

:   National Health and Nutrition Examination Survey

NICE

:   National Institute of Health and Clinical Excellence

NOGG

:   National Osteoporosis Guideline Group

Prevalence

:   The number of cases of disease (e.g. osteoporosis) for a given area or at a given time

Probability

:   The likelihood of an event, e.g. fracture. Fracture probability depends on two hazards---the incidence of fracture and the incidence of death

QALY

:   The QALY is a multi-dimensional outcome measure that incorporates both the quality (health related) and quantity (length) of life. The value of a QALY was set at value of 2× GDP per capita

QCT

:   Quantitative computed tomography

QoL

:   Quality of life

QUS

:   Quantitative ultrasound

SCOPE

:   Scorecard for osteoporosis in Europe

SD

:   Standard deviation

*T* score

:   Describes the number of standard deviations (SD) by which the BMD in an individual differs from the mean value expected in young healthy women. The operational definition of osteoporosis is defined as a value for BMD 2.5 SD or more below the young female adult mean (*T* score less than or equal to −2.5 SD).

WHO

:   World Health Organization

WTP

:   Willingness to pay, used in Health Technology assessment to describe the value that society or a health care payer is prepared to pay to gain a QALY. The value of a QALY was set at value of 2× GDP per capita.
